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Abbrevi at ions
Abbreviations used in this thesis are those recommended 
in the Biochemical Journal Instructions to Authors (revised 1978) 
with the following additions.
DA dopamine
DOBA 3,4-dihydroxybenzoic acid
DOPAC 3,4-dihydroxyphenylacetic acid
DOPET 3,4-dihydroxyphenylethanol
HVA 4-hydroxy-3-methoxyphenylacetic acid
(horaovanillic acid)
MIH melanocyte-stimulating hormone release-inhibiting
hormone (melanostatin)
3MT 3-0-me thyIdop ami ne hydrochloride
NA noradrenaline
TRH thyrotropin-releasing hormone (thyroliberin)
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Summary
The hypothalamic hormones melanostatin (MIH) and 
thyroliberin (TRH) have been shown by others to have a 
direct action on adrenergic neurons, distinct from their 
role in regulating the release of pituitary hormones. This 
present thesis examines the effect of MIH and TRH on the 
biosynthesis, release and oxidative deamination of dopamine 
in rat brain tissue preparations.
Neither MIH (10""^M) nor TRH (10~^M) altered monoamine 
oxidase activity in tissue slices or sucrose homogenates. 
Autoradiographic analysis showed that there were two products 
of the oxidative deamination of dopamine by striatal homo­
genates, one of which was DOPAC. Roughly equal amounts of
DOPAC and an unknown compound were formed. MIH and TRH did 
not alter the total amount of, or the distribution of label 
between, the two metabolites.
Neither MIH (10"^M) nor TRH (lO'^^M) had any effect on 
the rate of dopamine synthesis by striatal homogenates.
Calcium chloride (0.85 mM) stimulated dopamine synthesis by 
striatal synaptosomes incubated in 18.4 yM tyrosine, but 
neither MIH (10"^M) nor TRH (10”^M) altered the rate of 
dopamine synthesis. Neither peptide significantly stimulated 
the rate of dopamine synthesis in the presence of 0.85 mM 
calcium chloride.
Neither MIH (10”^M) nor TRH (10~^M) altered the rate 
of dopamine synthesis by striatal synaptosomes in the presence 
of 1.70 mM calcium chloride at 1.07 yM tyrosine. Tyramine, 
a sympathomimetic amine, inhibited dopamine synthesis, 50%
inhibition occurring at 3.3 x 10 ^M.
Both tyramine (10 ^M) and amphetamine (10 ^M) stimulated 
dopamine synthesis in the presence of 2 mîi EDTA but the 
magnitude of the drug-induced stimulation varied inversely 
with the basal rate of dopamine synthesis. TRH (10~^M) did 
not stimulate dopamine synthesis under these conditions.
Amphetamine (10”^M) stimulated release of dopamine from 
striatal synaptosomes in the presence of 1.25 mM calcium 
chloride and also in the presence of 2mM EDTA. MIH (10“^M)
_ Q
and TRH (10 M) stimulated release of dopamine only in the 
presence of calcium chloride.
These results suggest that MIH and TRH release dopamine 
from vesicular stores by exocytosis while amphetamine releases 
dopamine from a cytoplasmic pool regulating tyrosine hydroxylase.
INTRODUCTION
Introduction
The hypothalamic hormones are a group of low molecular 
weight peptide hormones synthesised by neurons in the hypo­
thalamus and stored in nerve endings in the median eminence. 
They are transported by the portal vessels to the pituitary 
gland where they regulate the release of the anterior 
pituitary hormones (Table la). (Blackwell and Guillemin,
1973; Reichlin et al., 1976; Schally et al., 1973, 1977).
The release of peptides from the hypothalamus is itself closely 
regulated. For example, neurotransmitters such as 
acetylcholine, dopamine and serotonin, and steroid hormones 
(Bennett et al., 1975a, b ; Edwardson and Bennett, 1974) can 
modify the release of the hypothalamic hormones. For example, 
dopamine stimulated the release of luteinizing hormone - 
releasing hormone (Bennett et al., 1975a), while acetylcholine 
stimulated the release of corticotropin-releasing hormone 
(CRH) (Edwardson and Bennett, 1974). Dopamine, however, 
inhibited the release of CRH (Edwardson and Bennett, 1974), 
but had no effect on the release of thyrotropin-releasing 
hormone (TRH) (Bennett et al., 1975a).
1.1 Role of Hypothalamic Hormones in Brain Function
The first indication that the hypothalamic hormones might 
have an extra-pituitary role came when it was found that some 
of the peptides, particularly melanocyte-stimulating hormone 
release-inhibiting hormone (MIH) and TRH (Fig. 1), had 
behavioural effects, some of which could also be detected in 
hypophysectomised rats. The idea of an extrapituitary role
Table la Hypothalamic Hormones controlling 
Release of Pituitary Hormones
Abbreviation Hypothalamic Hormone
CRH
TRH
LHRH
FSHRH
GHRH
GHRIH
PRH
PRIH
MRH
MIH
Corticotropin (ACTH)-releasing hormone 
Thyrotropin. (TSH)-releasing hormone 
Luteinizing hormone (LH)-releasing hormone 
Follicle-stimulating hormone (FSH)- 
releasing hormone
Growth hormone (GH)-releasing hormone 
Growth hormone (GH)-release-inhibiting 
hormone
Prolactin-releasing hormone 
Prolactin release-inhibiting hormone 
Melanocyte-stimulating hormone (MSH)- 
releasing hormone
Melanocyte-stimulating hormone (MSH) 
release-inhibiting hormone
Where the identity of the physiological hypothalamic 
hormone is unclear, the term 'factor' is often used 
instead of hormone. eg MRF = MSH-releasing factor. 
MSH is liberated from the intermediate lobe of the 
pituitary. All other pituitary hormones listed are 
liberated from the anterior lobe.
o
1
o
C N -  CHCNHCH^CNH^
H C H .
1 /
CH (CH^)^
L-prolyl- L- leucyl- glycinam ide 
MIH
NH — C H —  C — N
L-pyroglutamyl- L -hist idyl- L-proline amide
TRH
Fîg. 1 Molecular Structures of Ml H and TRH
was strengthened by the observation that as much as 80% of 
the total brain content of these hormones was found outside 
the hypothalamus (Table lb).
Table 2 summarises some of the behavioural effects of the 
hypothalamic hormones and indicates their possible site of 
action. For example, the hypothalamic hormones may act as 
neurotransmitters themselves since they depress the activity 
of central neurons or may act as modulators of aminergic or 
cholinergic neurons. The evidence implicating the hypothalamic 
hormones in the control of dopaminergic and noradrenergic 
neurons is given below to provide a background for discussing 
the possible mode of action of the hypothalamic hormones on 
catecholaminergic neurons.
1.2 Catecholamines and Behaviour
The catecholamines dopamine, noradrenaline and adrenaline 
are neurotransmitters in the brain (Hebb, 1970). The highest 
concentration of dopamine is found in the basal ganglia (Bertler 
and Rosengren, 1959a, b), regions in which there is very 
little noradrenaline, while noradrenaline is concentrated in 
the hypothalamus (Bertler, 1961; Carlsson et al., 1958;
8ano et al., 1959). Only small amounts of adrenaline are 
detectable in the central nervous system (Van der Gugten et al., 
1976).
Both the adrenal medullary catecholamines and brain 
catecholamines have been implicated in a wide range of 
behavioural functions (Barchas et al., 1972; Friedhoff, 1975). 
Correlations have been reported between catecholaminergic
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Table 2 Behavioural Effects of Hypothalamic Hormones
Behavioural Effects HypothalamicHormone
Possible Site 
of Action
L-dopa potentiation 
Plotnikoff and Kastin (1976)
TRH, MIH, 
LHRH, GHRIH
Apomorphine potentiation 
Plotnikoff and Kastin (1974) MIH '
Harraine antagonism 
Huidobro-Toro et al. (1975) MIH Dopaminergic
Oxotremorine antagonism 
Plotnikoff et al. (1972a) MIH
neurons
Deserpidine antagonism 
Plotnikoff et al. (1973) MIH
Induction of rotational 
behaviour 
Cohn et al. (1975)
TRH
Pentobarbital antagonism 
Breese et al. (1975)
Schmidt (1977), Yarbrough (1978) 
Yarbrough and Singh (1978)
TRH
Cholinergic
Induction of "barrel rotation" 
Cohn and Cohn (1975) GHRIH
neurons
Serotonin potentiation 
Plotnikoff and Kastin (1976) TRH, LHRH
Serotoninergic
neurons
Induction of shaking behaviour 
Wei et al. (1975) TRH
Morphine
receptors
Depressant action on central 
neurons 
Dyer and Dyball (1974) 
Renauld and Martin (1975) 
Renauld et al. (1975)
TRH, LHRH 
GHRIH
Peptidergic
Induction of mating behaviour 
Moss and McCann (1973)
Pfaff (1973)
LHRH
neurons
function and emotion, mood, stress, depression, psychosis, 
drug craving,learning and memory. Current hypotheses on 
the role of catecholamines in behaviour have been developed 
from the effects of drugs in producing and relieving 
behavioural malfunction.
The following account describes specific aspects of 
behaviour in which the hypothalamic hormones, as well as 
cerebral dopamine and noradrenaline, may be involved.
1.2.1 Dopamine and Locomotory Activity
There is extensive evidence suggesting an involvement 
of dopamine in regulating locomotory activity. The most 
definite connection between a dopaminergic system and a 
specific locomotory abnormality is the role of striatal 
dopamine in the motor disturbances involved in Parkinson's 
disease,
1.2.1.1 Parkinson ' s D.i sease
The most obvious biochemical abnormality of the 
Parkinsonian syndrome is dopamine depletion from the nigrostriatal 
nerve terminals (Hornykiewicz, 1966). Thus drugs which reduce 
striatal dopamine, for example reserpine, or antagonise 
dopamine receptors, for example chlorpromazine, produce a 
hypokinetic state in animals similar to Parkinsonism in man.
L-dopa (L-3, 4^ihydroxyphenylalanine), a precursor of dopamine 
which crosses the blood-brain barrier, reduces the symptoms of 
Parkinson's disease (Cotzias, 1969) and counteracts the effect 
of drugs reducing or blocking the effects of dopamine. The 
therapeutic action of L-dopa is unclear but presumably it must
increase striatal dopamine content. Thus drugs potentiating 
the effect of L-dopa may be of value in the treatment of 
Parkinson’s disease.
Cotzias et al (1967) demonstrated that melanocyte-stimulatinj 
hormone (MSH) aggravates the symptoms of Parkinson's disease. 
This, together with the observation that MIH potentiates the 
behavioural effects of L-dopa (see below), presumably by 
stimulating the formation of dopamine, and antagonises 
oxotremorine induced tremors (Plotnikoff et al., 1972a) even 
in hypophysectomised rats, suggested that MIH might be of 
value in the treatment of Parkinson's disease (Kastin, 1967). 
Though MIH did ameliorate some of the symptoms of Parkinson's 
disease, it is not known precisely how MIH exerts its 
therapeutic effects (Barbeau, 1974; Kastin et al., 1976).
1.2.1.2 Rotational Behaviour 
Rotation in Lesioned Rats
Rotation can be induced in rats lesioned unilaterally 
in the nigrostriatal tract by drugs influencing dopaminergic 
function of the basal ganglia (Click et al., 1976).
After lesioning of the substantia nigra, the dopamine 
neurons and terminals degenerate but the dopamine receptors 
remain intact. The receptors are believed to become super­
sensitive. Thus an imbalance between the nigrostriatal pathways 
on the two sides of the brain is created. Potentiation of 
this imbalance by dopaminergic agents is thought to induce 
rotation. Rotation occurs in the direction of the side of 
the brain in which less dopamine mediated activity occurs.
Thus presynaptic acting agents, for example amphetamine, 
affect the dopamine terminals only on the unlesioned side, 
with a resultant turning toward the lesion. In contrast, 
drugs which directly affect the receptors, for example 
apomorphine, will have a greater effect on the striatum 
of the lesioned hemisphere and produce a turning away from 
the lesioned side (Ungerstedt, 1971).
Rotation in Intact Rats
Rotational behaviour can also be induced in intact rats. 
Unilateral intrastriatal injection of dopamine or apomorphine 
produced turning away from the side of drug administration, 
an effect that can be blocked by prior bilateral intrastriatal 
injection of chlorpromazine. Moreover, unilateral injection 
of chlorpromazine alone produced turning toward the side of 
injection (Ungerstedt et al., 1969).
High doses of amphetamine (15 - 25 mg/kg) induced rotation 
in normal rats resembling that induced by lower doses ( 1 - 5  mg/k^ 
in lesioned rats (Jerussi and Glick, 1974). This suggested 
the presence of an intrinsic and normal bilateral imbalance 
in dopamine content of left and right nigrostriatal systems and 
that potentiation of this imbalance by amphetamine produced 
rotation.
In agreement with this suggestion, Glick et al. (1976) 
found that the dopamine content of left and right striata différée 
by 10 - 15%. After amphetamine administration, the dopamine 
content of left and right striata differed by approximately 
25%, In response to amphetamine, rats consistently rotated 
away from the side containing the higher level of dopamine.
Intracerebroventricular injection of TRH (0.3 - 0.5 mg/kg) or 
amphetamine (1.0 - 1.5 mg/kg) induced rotational behaviour in 
non-lesioned rats pretreated with intraperitoneal injection of 
either apomorphine (4 mg/kg) or reserpine (4 mg/kg). Pre­
treatment with apomorphine led to clockwise rotation while 
pretreatment with reserpine led to counterclockwise rotation.
The direction of rotation depended only on the drug used for 
pretreatment as the direction was the same whether the drug 
was injected into the left or right lateral ventricle. 
Intracerebroventricular administration of TRH (0.3 - 0.5 mg/kg) 
or amphetamine (1.0 - 1.5 mg/kg) or apomorphine (1.0 - 1.5 mg/kg) 
or reserpine (1.0 - 1.5 mg/kg) alone did not induce rotation 
(Cohn et al., 1975) . Presumably pretreatment with apomorphine 
and reserpine produced an imbalance in dopamine content 
between left and right sides of the brain. Potentiation of 
this imbalance by TRH and amphetamine would induce rotational 
behaviour. This suggested that TRH, like amphetamine, could 
stimulate release of dopamine from presynaptic neurons.
1.2.1.3 L-dopa Potentiation Test
The L-dopa potentiation test (Everett, 1966), a test used 
for screening anti-depressant drugs, provides further evidence 
for the involvement of dopamine in locomotory behaviour.
In this test, mice are given pargyline, a monoamine 
oxidase inhibitor, orally and after 4 hours are injected 
intraperitoneally with L-dopa. The drug under study is 
given at selected times, for example, 1, 4, 8 or 24 hours 
before L-dopa. After L-dopa administration, the behavioural
response of groups of 4 mice to the drug are observed for 
1 hour. A typical response consists of a series of 
behavioural responses including marked irritability and 
motor reactivity, for example, piloerection, increased 
salivation, jumping, squeaking, fighting. This response 
is rated slight (1), moderate (2) or marked (3) potentiation 
of L-dopa depending on the extent of the response. The 
hypothalamic hormones MIH, TRH, GHRIH and LHRH (Plotnikoff 
and Kastin, 1976) and the tricyclic antidepressant drugs 
imipramine, noriraipramine and amitriptyline (Everett, 1966), 
all potentiate the behavioural effects of L-dopa. This 
suggested that the hypothalamic hormones might potentiate 
the effects of L-dopa by inhibition of reuptake of dopamine.
The potentiation of L-dopa by MIH and TRH was 
independent of the presence of a number of somatic organs 
including the pituitary gland (Plotnikoff et al., 1971, 
1972a, b, 1974a, b, c). This indicated an extrapituitary 
effect of the hypothalamic hormones on the central nervous 
system. Further, animals pretreated with FLA-63 
[bis-(1-methy1-4-homopiperaziny1-thiocarbony1)-disulfide] , 
a doparaine-3“hydroxylase inhibitor, before subjected to the 
L-dopa potentiation test still respond to TRH (Plotnikoff 
and Kastin, 1976) suggesting that TRH acts through 
dopaminergic, rather than noradrenergic, neurons.
1.2.2 Noradrenaline and Depression
The catecholamine hypothesis of affective disorders 
(Bunney and Davis, 1965; Schildkraut, 1965) proposed
that some, if not all depressions are associated with a 
decrease in catecholamines, particularly noradrenaline, 
at certain central synapses. Conversely, mania may be 
associated with an excess of such amines. At least two 
subgroups have been identified. In one group patients 
may have an alteration in noradrenergic systems, probably 
central, which is related to their depressive states as prior 
to treatment, low levels of 4-hydroxy-3-methoxyphenylethylene- 
glycol (MOPEG), a degradation product of noradrenaline, are 
found in the cerebrospinal fluid and urine of patients. In 
the second group serotonin systems may be altered as patients 
respond to amitriptyline (which inhibits reuptake of 
serotonin) but not to amphetamine (which inhibits reuptake 
of noradrenaline and dopamine). Further, these patients 
had normal urinary levels of MOPEG.(Maas, 1975).
The actions of both the major classes of antidepressants, 
the monoamine oxidase inhibitors and the tricyclic anti­
depressants, may be mediated by noradrenaline. For example, 
iproniazid, a monoamine oxidase inhibitor, increases the 
concentration of cerebral monoamines, while imipramine, a 
tricyclic antidepressant, inhibits reuptake of noradrenaline 
and serotonin. These drugs increase the availability of 
noradrenaline and serotonin at central synapses and this 
effect is thought to underlie their therapeutic action.
A revised catecholamine hypothesis of affective 
disorders (Ashcroft et al.,1972; Bunney et al., 1977) 
suggests that depression might reflect a state of pathologic
hyposensitivity of postsynaptic noradrenergic receptors in 
brain. Thus the therapeutic action of antidepressants might 
be related to postsynaptic rather than presynaptic mediated 
events and would involve an increase in receptor sensitivity.
Reserpine causes depression presumably by depleting 
amine storage vesicles in presynaptic neurons (Schildkraut, 
1965). However, reserpine can also increase the sensitivity 
of the limbic noradrenergic receptor-coupled adenylate 
cyclase system to noradrenaline (Williams and Pirch, 1974).
This would result in feedback inhibition of noradrenaline 
synthesis and a decrease of noradrenaline at functional 
synapses. The action of tricyclic antidepressants and 
monoamine oxidase inhibitors would in this case be to 
desensitise hypersensitive noradrenaline receptors and to 
reduce the feedback inhibition of the biosynthesis of 
noradrenaline (Sulser et al., 1978).
TRH has been claimed to be effective in the treatment 
of depression (Kastin et al., 1972; Prange et al., 1972) 
but there is much disagreement (Benkert et al., 1974; 
Dimitrikoudi et al., 1974; Hollister et al., 1974). TRH 
could exert its antidepressant effect by action on the 
presynaptic neuron, for example, by inhibiting monoamine 
oxidase or by desensitisation of hypersensitive postsynaptic 
noradrenergic receptors.
Conclusions
An account has been given of some examples of the 
behavioural effects of catecholamines in which the hypothalamic
hormones also play a role. Evidence has been presented that 
the behavioural effects of the hypothalamic hormones might be 
mediated by catecholamines but as yet there is no conclusive 
evidence.
The metabolism of catecholamines is now described and 
ways in which the metabolism of catecholamines might be regulated 
indicated to provide a background for discussing possible ways 
in which the hypothalamic hormones might regulate catecholamine 
metabolism and thus influence behaviour.
1.3.1 Metabolism of Catecholamines
The catecholamines are formed in brain from their amino 
acid precursor tyrosine according to the scheme shown in 
Fig. 2. This sequence of enzymic steps which was first 
demonstrated in the adrenal medulla (Blaschko, 1939) has now 
been confirmed in the brain (Mandel, et al., 1975).
Biosynthesis
Tyrosine is taken up from the bloodstream and concentrated 
in presynaptic nerve endings in the brain. In the cytoplasm 
of these nerve endings, tyrosine is converted to dopa by the 
enzyme tyrosine hydroxylase. Tyrosine hydroxylase, the rate 
limiting enzyme in the biosynthetic pathway, requires oxygen, 
ferrous iron and a reduced pteridine cofactor for activity 
(Nagatsu et al., 1964). The enzyme is subject to feedback 
inhibition by catechols, particularly dopamine (Kuczenski and 
and Mandell, 1972).
Dopa is rapidly converted to dopamine by dopa decarboxylase 
(Holtz et al., 1938), a pyridoxal phosphate requiring enzyme.
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Fig. 2 Metabolism of Catecholamines
Dopa decarboxylase has been renamed aromatic amino acid 
decarboxylase in view of its lack of specificity (Lovenberg 
et al. , 1962). Both hydroxylation and decarboxylation steps 
apparently occur within the cytoplasm of nerve terminals.
Dopamine is converted to noradrenaline by dopamine-3-hydroxylase 
(Udenfriend and Creveling, 1959), a copper containing enzyme.
This enzyme is localised in the same storage particles as 
those containing the bulk of noradrenaline. Phenylethanolamine- 
N-methyl transferase (Pohorecky et al., 1961; Saavedra et al., 
1974), where present, is located in the cytoplasm and catalyses 
the conversion of noradrenaline to adrenaline.
Release
There are two mechanisms by which catecholamines can be 
released from sympathetic nerve terminals (Smith, 1973).
The first, exocytosis, exhibits an absolute requirement for 
calcium. The second, displacement diffusion, is not calcium 
dependent. In the central nervous system, depolarisation- 
induced release of catecholamines (Arnold et al., 1977;
Blaustein et al., 1972) is thought to occur by exocytosis.
In contrast, release of catecholamines by tyramine (Patrick and 
Barchas, 1976) and amphetamine (Ziance et al., 1972) is thought 
to occur by displacement diffusion. Once in the synaptic cleft, 
the catecholamines can exert an effect on a post-synaptic cell.
Inactivation
After the catecholamines have exerted an effect on a 
postsynaptic cell, their action must be terminated. In the 
central nervous system catecholamines have their action
terminated chiefly by reuptake CIversen, 1974).
1,3.2 Control of Catecholamine Metabolism
Fig. 3 represents a model of a central noradrenergic 
neuron and indicates the various sites at which drugs might 
interact with catecholamine metabolism. Some of these drugs 
are listed in Table 3, together with their site of action.
Interaction of drugs at some of these sites could increase 
the concentration of catecholamines at central synapses. An 
increase in catecholamine concentration could result from 
stimulation of catecholamine release, for example by 
amphetamine, or by inhibition of reuptake, for example by 
imipramine or by stimulation of catecholamine synthesis.
Tyrosine hydroxylase is the enzyme most susceptible to 
pharmacological manipulation as it is the rate limiting step 
in catecholamine synthesis. An increase in catecholamine 
synthesis could be achieved by direct action on the enzyme, 
for example, by altering its physical state (Kuczenski, 1975a). 
An increase in catecholamine synthesis could also be achieved 
indirectly, for example, by increasing release of dopamine 
from a pool inhibiting tyrosine hydroxylase (Kuczenski, 1975b) 
or by blockade of postsynaptic receptors (Fuller and Steinberg, 
1976).
1.3.2.1 Possible Mode of Action of Hypothalamic Hormones 
on Catecholamine Metabolism 
The behavioural effects of the hypothalamic hormones 
suggest that they are most likely the result of an increase 
in activity of central dopaminergic or noradrenergic neurons
iy
tyrosine ^ tyrosine
Presynaptic cell
dopa
DA
deaminated
metabolitesMAO
NA
NA
NA COMT O-methylated 
metabolites
Postsynaptic cell
Site 1 Precursor transport
Site 2 Tyrosine hydroxylase
Site 3 Dopa decarboxylase
Site 4 Dopamine-yf -hydroxylase
Site 5 Monoamine oxidase (MAO)
Site 6 Storage
Site 7 Release
Site 8 Interaction with receptors
Site 9 Reuptake
Site 10 Catechol -O-methyl transferase (COMT)
Fig, 3 Model of Central Noradrenergic Neuron
Table 3 Some Drugs Interfering with Catecholamine Metabolism
Drug Action on Catecholaminergic Neurons
a-methy1-p-tyrosine
Tyramine
Amphetamine
Pargyline, 
Amitriptyline
Pyrogallol
Apomorphine
Haloperidol, 
Chlorpromazine
Isoprenaline
Phentolamine
Reserpine
6-hydroxydopamine
Inhibits tyrosine hydroxylase
Stimulates release
Stimulates release 
Inhibits reuptake 
Inhibits monoamine oxidase
Inhibit reuptake
Inhibits catechol-0-methyl 
transferase
Stimulates dopamine receptors
Block dopamine receptors
Stimulates 6-noradrenaline 
receptors
Blocks a-noradrenaline receptors
Depletes storage vesicles
Destroys catecholaminergic neurons
^ JL
which could raise the concentration of dopamine or noradrenaline 
at central synapses. However, in general, it has been found 
that the hypothalamic hormones do not increase the endogenous 
levels of catecholamines (Kastin et al., 1975; Kostrzewa et al., 
1974; Plotnikoff et al., 1974a, 1975). Thus an increase in 
synthesis and/or release or a decrease in degradation, of 
catecholamines is more likely.
Biosynthesis
Direct evidence in support of the idea that hypothalamic 
hormones stimulate biosynthesis of catecholamines is that MIH 
induced a dose-related increase in striatal dopamine synthesis 
in slices obtained from treated normal rats (Friedman et al., 
1973) while TRH stimulated the conversion of [^^C] tyrosine to 
[^^Cj noradrenaline in rat brain (Keller et al., 1974) . There 
is indirect evidence that MIH and TRH stimulate catecholamine 
biosynthesis. TRH increased the conversion of cerebral 
noradrenaline to normetanephrine (Horst and Spirt, 1974) without 
altering the endogenous noradrenaline content, thus implying a
concomitant increase in noradrenaline synthesis.
Release
Stimulation of release is also a possible site of action of 
MIH and TRH, as TRH stimulated release of [^H] noradrenaline 
from hypothalamic synaptosomes and [^H] dopamine from striatal 
synaptosomes (Horst and Spirt, 1974) . Preljjminary results 
suggested that MIH stimulated release of dopamine from striatal
slices (Mulder and Smelik, 1975).
Further, TRH facilitated the decrease of brain noradrenaline
produced after administration of the tyrosine hydroxylase 
inhibitor a-methyl-p-tyrosine ÇBreese et al., 1974;
Constantinidis et al., 1974; Keller et al., 1974). As no 
change in the level of noradrenaline was detected after 
administration of TRH alone. (Constantinid,is et al., 1974 ;
Keller et al., 1974) it must be assumed that an increase in 
synthesis compensated for the increase in release and catabolism. 
This suggested that the turnover of noradrenaline was enhanced 
by TRH. MIH accelerated a-methyl-p-tyrosine induced disappearance 
of dopamine in rat brain, suggesting that MIH, like TRH, could 
stimulate release and turnover of catecholamines (Pugsley and 
Lippmann, 1977).
Inactivation
Inhibition of catecholamine reuptake is not considered a 
likely site of action of MIH and TRH as MIH (Kostrzewa et al., 
1976) and TRH (Horst and Spirt, 1974) did not affect the
o
uptake of [ H] dopamine by striatal synaptosomes, TRH did not 
prevent uptake of [^H] noradrenaline into hypothalamic
O
synaptosomes (Horst and Spirt, 1974) or uptake of [ H] dopamine 
or [^ h ] noradrenaline into rat brain synaptosomes under the 
experimental conditions in which imipramine caused greater 
than 50% inhibition of reuptake (Tuomisto and Mannisto, 1973).
If MIH and TRH. do inhibit the degradation of dopamine and 
noradrenaline then the enzymes monoamine oxidase and catechol- 
0-methyl transferase are possible sites of action. However,
TRH may not inhibit monoamine oxidase (Breese et al., 1974). 
Impairment of 0-methylation may be a possible extra-hypophyseal 
mechanism of action of MIH. (Carman, 1973) as MIH caused a
decrease in urinary HVA without a concomitant dimunition of 
urinary DOPAC (Sandler et al, 1973).
1.4 Comparison of the Effects of the Hypothalamic Hormones,
MIH and TRH and Amphetamine
Evidence is accumulating, mainly from behavioural studies, 
that the effects of TRH and to a lesser extent MIH, are in 
many ways similar to those produced by amphetamine.
MIH induced stereotyped behaviour in cats similar to that 
seen after amphetamine administration (North et al., 1973).
TRH induced rotational behaviour in non-lesioned rats like that 
induced by amphetamine (Cohn et al., 1975) and also produced 
amphetamine^like effects in mice (Malik, 1976) and rabbits 
(Horita and Carino, 1975). In the yohimbine screening test 
for anti-depressant drugs, TRH acted more like amphetamine 
than like a tricyclic drug (for example, imipramine) or a 
monoamine oxidase inhibitor (Hine et al., 1973). Clinically, 
TRH administration leads to a worsening in the state of 
schizophrenia, an effect that is also seen when amphetamine is 
given (Bigelow et al., 1975; Davis et al., 1975). Further, 
intravenous injection of TRH causes characteristic changes in 
the electroencephalogram of conscious patients resembling 
those produced by amphetamine and protriptyline (Itil, 1974).
Conclusions
Evidence suggests the hypothalamic hormones, like 
amphetamine, influence behaviour and that they may do this by 
stimulating the release and turnover of catecholamines. Thus 
the aim of this thesis is to study the relationship between the
behavioural effects of the hypothalamic hormones and 
catecholamine metabolism and to see if this leads to an 
interpretation of the behavioural effects. In addition 
the biochemical effects of the hypothalamic hormones, MIH 
and TRH, are compared with those of amphetamine to see if 
the common behavioural effects have a common biochemical 
basis.
1.5 Methods of Studying the Effects of Hypothalamic Hormones
on Catecholamine Metabolism
Most studies investigating the effects of hypothalamic 
hormones on catecholamine metabolism have involved the 
intraperitoneal injection of MIH or TRH with subsequent 
measurement of some aspect of catecholamine metabolism, for 
example biosynthesis of catecholamines. On intraperitoneal 
administration of MIH or TRH it is unclear how much peptide 
can actually enter the brain as their ability to penetrate 
the blood-brain barrier may be poor (Dupont et al., 1975; 
Pelletier et al., 1975; Witter, 1975). Even if peptides do 
cross the blood-brain barrier it is uncertain which brain 
regions would be affected. Further, the half-life of 
exogenous peptides in plasma is very brief (May and Donabedian, 
1973; Redding et al., 1973). For this reason it was decided, 
in this thesis, to add MIH and TRH to in vitro tissue systems.
As MIH and TRH may, like amphetamine, stimulate release 
and biosynthesis of dopamine or inhibit monoamine oxidase, 
it was decided to examine the effect of MIH and TRH on these 
three presynaptic dopaminergic mechanisms.
II MATERIALS AND METHODS
2.1 Materials
Analar reagents were used throughout.
Fine chemicals were obtained as follows.
R a d i o c h em i c a1s
[ethylamine-l-^^C] dopamine hydrochloride specific activity
52 mCi/mmol
l^ethylamine-1, 2-^h] dopamine hydrochloride specific activity
10 Ci/mmol
L- [ ]  tyrosine specific activity
486 raCi/mraol
L-[side chain-2,3-^H] tyrosine specific activity
22 Ci/mmol
from Radiochemical Centre, Amersham, Bucks, U.K.
[^^C] toluene specific activity
5,26 X 10^ dpm/g 
toluene specific activity
2.58 X 10^ dpm/g 
from Packard Instrument Co. Inc., Caversham, Berks, U.K.
Reducing agents and inhibitors
Ascorbic acid BDH Chemicals Ltd., Poole,
Dorset, U.K.
Nicotinamide adenine dinucleotide PL Biochemicals Inc. 
reduced, disodium (NADH) c/o International Enzymes Ltd
Windsor, Berks, U.K.
Pargyline hydrochloride Abbott Labs., Queenborough,
Kent, U.K.
Drugs
Tyramine
Melanostatin
Thyroliberin
(+)-Amphetamine sulphate
)
Standards for autoradiography 
Tyrosine ^
Dopamine hydrochloride 
Noradrenaline hydrochloride
3.4-dihydroxybenzoic acid j
3.4-dihydroxyphenylethanol
3-0-methyldopamine hydrochloride
3,4-dihydroxyphenylacetic acid
4-hydroxy-3,methoxyphenylacetic acid 
Other chemicals
Silica gel sheets
Aluminium oxide, neutral, Brockman 
Grade 1 (alumina)
N-tris (hydroxymethyl) methyl glycine 
(Tricine)
BDH Chemicals Ltd.,
Pierce, Pierce and 
Warriner Ltd., Cheshire, 
U.K.
Pierce or
Serva, c/o Micro-Bio Labs, 
London, U.K. 
generously supplied by 
Dr D. Pollock, Dept, of 
Pharmacology, University 
of Glasgow.
BDH Chemicals Ltd.
Regis Chemical Co. 
c/o Micro-Bio Labs.
Aldrich Chemical Co., 
Wembley, Middlesex, Ü.K
Camlab, Cambridge, U.K.
BDH Chemicals Ltd.
Bovine plasma albumin
Sodium pyruvate
Armour Pharmaceutical Co 
Eastbourne, Essex, U.K. 
Sigma London Chemical Co 
Ltd., Poole, Dorset, U.K
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2.2 Tissue Preparation
Brains of adult male Wistar rats (200 + 25g) were 
dissected according to the method of Glowinski and Iversen 
(1966) into the following regions: cerebellum, medulla-pons,
hypothalamus, midbrain, striatum, hippocampus, cortex (Fig. 4)
2.2.1 Tissue Slices
Tissue from cortex-striatum, medulla-pons and cerebellum 
was chopped to small fragments using a McIIwain tissue chopper 
(McIIwain and Buddie, 1953) set on 0.26 mm and suspended in 
1 ml of phosphate-saline.
2.2.2 Sucrose Homogenates
Tissue from cortex, striatum, medulla-pons and 
cerebellum was homogenised in 4 vol of ice-cold 0.3 M sucrose 
using ten strokes of a hand operated glass-glass homogeniser 
(clearance 0.25 mm),
2.2.3 Crude Synaptosomes (Pg fraction)
This preparation was made at 0 - 4°C according to the 
scheme outlined in Fig. 5.
Striatal tissue was homogenised in 10 vol of ice-cold 
0.3 M sucrose, centrifuged at 1,000 g for 15 min and the 
supernatant (8^) recentrifuged at 17,000 g for 20 min. The 
pellet formed was resuspended in 0.3 M sucrose to give the P^ 
fraction (Gray and Whittaker, 1962).
Electron micrographs of the P^ fraction were prepared by 
Mr. I. Montgomery of the Electron Microscopy Unit, Department 
of Physiology, University of Glasgow.
Fig, 4 Regions of the Brain 
(a) Sagittal section
midbrainhippocampuscortex
cerebellum
medulla-pons
hypothalamus
b) Coronal section, half of brain is shown
- cortex
striatum
midbrain
hypothalamus
Preparation of Fraction
10% homogenate of striatal tissue in 0 .3  M sucrose
centrifuged at
1,000 g for 15 min
supernatant
(S,)
centrifuged at
17,000 g for 20 min
discarded
pelletsupernatant
I
resuspended 
in 0 .3  M sucrose
V
pellet
(Pi)
discarded
Fia, 5 ?2 fraction
2.2.4 Salines
Salines are based on Krebs (1950) in which constituent 
solutions are isotonie with 0.154 M NaCl.
1) Phosphate-saline contained 13.85 raM sodium phosphate 
buffer, pH 7.4, 116.1 mM NaCl, 3.55 mM NaHCOg, 4.74 mM KOI, 
1.18 mM MgSO^, 1.18 mM KHgPO^ and 11.54 mM glucose. pH of 
saline was 7.4.
2) Tris-saline contained 21.32 mM Tris-HCl, pH 7.4, 
instead of sodium phosphate buffer (Phizackerley and Fixter, 
1973). CaClg, where present, replaced an equal volume of 
isotonie NaCl. pH of saline was 7.3.
Salines containing ascorbic acid were prepared fresh 
daily. Addition of ascorbic acid lowered the pH of the 
saline to 7.2. Addition of EDTA lowered the pH to 6.6.
2.3 Assays
2.3.1 Fluorimetric Assay of Dopamine and Noradrenaline in 
Hypothalamus and Striatum 
Dopamine and noradrenaline were determined by a 
modification of the method of Shellenberger and Gordon (1971)
Extraction and Isolation of Dopamine and Noradrenaline
Tissue samples (100 - 150 mg hypothalamus; 250 - 300 mg 
striatum) were homogenised in 3 ml of 0.4 M perchloric acid 
containing 1 g Na^S^O^ and 1 g EDTA per 1. The homogenates 
were left to stand on ice for 10 min then centrifuged at
20,000 - 28,000 g for 15 min. The supernatant was removed 
and adjusted to 6 ml with 0.4 M perchloric acid. The pH 
was adjusted to 8.0 with Tricine solution (17.9 g Tricine
and 25 g disodium EDTA per 1 of 0.5 M NaOH). Dopamine and 
noradrenaline were adsorbed on to columns of alumina (300 mg) 
in pasteur pipettes plugged with glass wool. The columns 
were washed with 10 ml of distilled water then sucked dry 
before elution of dopamine and noradrenaline with 3 ml of 
0.05 M perchloric acid. Recovery of dopamine was 6 3 7%
(n=6); of noradrenaline 79 + 7% (n=15) (means + S.D.).
Estimation of Dopamine and Noradrenaline
1 ml of 0.05 M perchloric acid eluate was adjusted to 
pH 6.5 with 1.5 ml of 0.1 M phosphate-EDTA solution (9 g 
disodium EDTA added to 11 of 0.1 M phosphate buffer and the 
pH adjusted to 7.0 with 5.0 M NaOH). 0.2 ml of iodine 
reagent (0.1 M, 2 g potassium iodide plus 0.5 g iodine in 
a final vol. of 40 ml) was added and the solution mixed 
immediately. After exactly 2 min, 0.5 ml of alkaline sodium 
sulphite solution (2.5%; 1 ml of a solution containing 250 mg/
ml sodium sulphite diluted to 10 ml with 5.0 M NaOH) was added 
and the solution mixed again. After 2 min, 0.4 ml of glacial 
acetic acid was added and the solution heated in a boiling 
water bath for 3 min, cooled on ice for 5 min and the 
fluorescence due to noradrenaline read at room temperature in 
an Arainco Bowman spectrophotofluorometer (V.A. Howe and Co. Ltd., 
London, U.K.), slit no. 5, 800 V, sensitivity 100 (activation 
peak 375 nm; fluorescence at 485 nm).
Samples were heated at 100°C for an additional 5 min.
After cooling, the dopamine fluorescence was read at 0 - 4^C 
(activation peak 320 nm; fluorescence at 370 nm). Tissue
blanks were developed by reversing the order of addition 
of the iodine and alkaline sulphite solutions.
Standard curves for estimation of dopamine and 
noradrenaline are shown in Figs. 6 and 7 respectively.
Samples containing 100 ng dopamine and 100 ng 
noradrenaline were included in each series of determinations 
and used to convert fluorescence (relative intensity) to 
ng dopamine or noradrenaline.
2.3.2 Biosynthesis of Dopamine
Brain tissue was incubated with radioactive tyrosine 
and the dopamine formed separated from tyrosine by alumina 
adsorption as described above.
0,1 ml of sucrose homogenate (2 mg protein) was 
preincubated for 10 min in 0.2 ml of 0.28 M phosphate buffer, 
pH 6.2 (McGeer et al., 1967) using air as the gas phase.
The reaction was started by the addition of 1 yCi of 
L-[U“ '^^ C] tyrosine.
0.1 ml of Pg fraction (0.4-0.7 mg protein) was 
preincubated with 0.1 ml of Tris-saline for 5 min and the 
reaction started by the addition of 0.1 ml of Tris-saline 
containing 1 yCi of L-[side-chain-2,3-^h ] tyrosine.
All assays were terminated by the addition of an equal 
volume of ice-cold 0.8 M perchloric acid containing 2 g 
NagSgO^ and 1 g EDTA per 1. 200 yg dopamine was added as
carrier and homogenates centrifuged at 20,000-28,000 g 
for 15 min. The supernatant was removed and adjusted to 
5 ml with 0.4 M perchloric acid. The pH was adjusted to
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8.0 with Tricine solution (17.9 g and 25 g disodium EDTA 
per 1 of 0.5 M NaOH). Catechols were adsorbed on to 
columns of alumina (300 mg) which were washed with 10 ml 
of distilled water and catechols eluted with 3 ml of 0.4 M HCl. 
Recovery of carrier dopamine was greater than 70%.
For estimation of [^^C] catechols, 10 ml of 'Triton' 
scintillant (Triton X-100, 1,000 ml; toluene 2,000 ml;
PPO 15 g; POPOP 1.5 g) was added to 3 ml of the acid eluate 
to give a stable emulsion (Turner, 1968). Counting efficiency 
was greater than 45%. For [^H] catechols, 10 ml of 'Triton' 
scintillant was added to 1 ml of column effluent for 
estimation by liquid scintillation counting. Counting 
efficiency was greater than 30%.
Isotope added to incubation medium was used as the 
reagent blank. Blank values were 1,500-1,800 cpm in 
experiments using [^^C] tyrosine as substrate. When [^H] 
tyrosine was used as substrate, blanks were 500-1,000 cpm. In 
general, sample counts were at least 10 times blank values.
Counts were converted to pmol dopamine per min using the 
formula : -
specific activity of tyrosine (nmol/yCi) x dpm in eluate gffic'iScy '(%')' ^  
dpn/iiCi (2.2 X 10®) x time of incubation (min) x recovery from alumina (%)
Identification of Reaction Products
The identification of products formed was confirmed by 
autoradiography.
Acid eluates from alumina columns were dried down iji vacuo 
and the residues taken up in 10 pi of acetone: 0.1 M HCl
( 9 : 1  v/v) for chromatography in two dimensions on plastic 
backed silica gel sheets (10 cm x 10 cm) together with 2 yg 
each of the following standards : - tyrosine, dopamine, DOPAC 
and HVA. The following solvent systems were used : -
(1) 1st dimension - the organic phase of chloroform :
acetic acid : H^O (2 : 2 : 1 by volume) (Osborne et al., 1975)
(2) 2nd dimension - butan-l-ol : pyridine : acetic acid :
HgO (15 : 2 : 3 : 5 by volume) (Aures et al., 1968).
Standards were detected using diazotized sulphanilic acid 
(Sandler and Ruthven, 1969) and radioactive compounds located 
by autoradiography using Kodirex X-ray film (KD 54T).
A chromatographic map showing the separation of tyrosine 
from its metabolites is shown in Fig. 8.
2.3.3 Oxidative Deamination of Dopamine
Tissue slices and sucrose homogenates were incubated 
with radioactive dopamine and the monoamine oxidase products 
extracted with ethyl acetate using a modification of the 
method of McCaman et al. (1965).
Tissue slices (5.8-20 mg protein in 1 ml of phosphate- 
saline) and sucrose homogenates (0.1 ml(l.5-2.0 mg protein) in 
0.2 ml of 0.28 M phosphate buffer, pH 6.2) were incubated for 
30 min with 0.2 yCi of [ethylamine-l-^'^C] dopamine hydrochloride 
The reaction was terminated by the addition of HCl to give a 
final concentration of 0.4 M. Tissue samples were homogenised 
in 1 ml of 0.4 M HCl and cooled to -20^C for 30 min.
Precipitated protein was removed by centrifugation at 3,000 rpm 
for 15 min (MSE bench centrifuge, Measuring and Scientific 
Equipment, London, U.K.). 2 ml of ethyl acetate was added
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Chromatographic Map to Show the Separation of Tyrosine and its 
Metabolites after 2~Dimensional Chromatography.
Q  HVA
^  DOPAC
1st
Î
o
a O d a
‘— > 2nd 1NA
Fig. 8. Tyrosine, dopamine, DOPAC and HVA were separated on silica 
gel sheets using the following solvent systems as described (2 .3 .2 ).
1st dimension -  the organic phase of chloroform : acetic acid ; HgO 
( 2 : 2 :  1 by volume)
2nd dimension -  butan-l-ol : pyridine ; acetic acid : H^O 
( 15 :2  ; 3 : 5 by volume)
DA -  Dopamine
DOPAC- 3 ,4-dihydroxyphenylacetic acid 
HVA -  4-hydroxy-3-methoxy-phenylacetic acid 
NA -  noradrenaline
tyr -  tyrosine
to eacli sample and the monoamine oxidase products extracted 
into the organic layer by vigorous mixing for 30 s. After 
centrifugation (MSE bench centrifuge, 1,000 rpm, 5 min) 1.5 ml 
of the organic layer was washed with 1 ml of 0.4 M HCl and 
the radioactivity in 1 ml estimated by liquid scintillation 
counting. Counting efficiency was greater than 70%.
Identification of Reaction Products
The identity of the products was checked by autoradiography 
as described for biosynthesis studies. Ethyl acetate layers 
were dried down in vacuo and the residues extracted 4 times 
with 10 yl of ethyl acetate. The extracts were chromato­
graphed on silica gel sheets together with 2 yg each of 
dopamine, DOPAC, HVA, 3MT and DOPET using solvent system 1 
(the organic phase of chloroform : acetic acid : H^O 
(2 : 2 : 1 by volume)).
The radioactive spots were scraped off the chromatograms 
and dispersed in a stable emulsion formed by adding 0.9 ml 
of water to 3 ml of 'Triton' scintillant. The radioactivity 
was determined by liquid scintillation counting. The results 
are expressed as a percentage of counts recovered.
2.3.4 Release of Dopamine
Release of dopamine was measured using a modification of 
the method of Eitan and Hershkowitz (1977).
2.5 ml of fraction (11-16 mg protein) was diluted with 
9 vol of Tris-saline containing 0.13 mM pargyline, 1.14 mM 
ascorbic acid (TSPA) 1.25 mM CaCl^ and 10 yM EDTA and the 
diluted suspension preincubated at 37°C for 5 min. Uptake
was terminated by centrifugation at 10,000 g for 15 min at
4^0 and the resulting pellet rinsed twice with 4 ml of ice-
cold TSPA containing either 1.25 mM CaClg (TSPAC) or 2 mM 
EDTA (TSPAE),
The pellet was resuspended with 2.5 ml TSPAC or TSPAE 
and 0.1 ml aliquots of the suspension were added to 2.9 ml
TSPAC or TSPAE at 37^C containing the drug to be tested in
its final concentration. Dopamine release was allowed to 
proceed for 2 min at 37°C with shaking. Release was 
terminated by the addition of 3 ml of ice-cold TSPAC or TSPAE 
and centrifugation at 10,000 g for 15 min at 4°C. The 
supernatant was collected and the pellet dissolved in 2 ml 
of 3% sodium dodecyl sulphate at 20^C for 30 min. The 
radioactivity in 1 ml of supernatant and pellet was estimated 
by liquid scintillation counting. Counting efficiency was 
greater than 30%.
[^H] dopamine released is expressed as:-
_counts in supernatant____________________  x 100%
counts in supernatant + counts in pellet
The radioactivity released from 0,1 ml aliquots of P^ fractions 
incubated at O^C was used as a blank value and subtracted from 
all results.
2.3.5 Preparation of Standard Curves for Determination 
of Efficiency of Counting
250 ]il of standard radioactive toluene solution ( [^H] 
toluene 2.58 x 10^ dpm/g or [^^C] toluene 5.26 x 10^ dpm/g; 
density of toluene 0.866) was weighed in a glass scintillation
vial then diluted to 250 ml with 'Triton' scintillant.
10 ml aliquots of the 'Triton' scintillant containing 
radioactive standard was dispensed into glass counting vials 
containing quenching agent. The vials were capped and 
mixed by vigorous hand shaking for 30 s then placed in the 
counter to cool for 30 min before counting. Samples were 
counted either by the sample channels ratio method using a 
Nuclear Chicago Isocap 300 (G.D. Searle, High Wycombe, Bucks.) 
or by the external standard ratio method using an Intertechnique 
SL4000 PG4000 (Uxbridge, Middlesex, U.K.). In general, 
samples were counted to give at least 5,000 cpm to ensure 
statistical accuracy.
The efficiency of counting of tritiated samples quenched 
with 0.4 M HCl is shown in Fig, 9,
2.3.6 Lactate Dehydrogenase (LDH)
0.1 ml of Pg fraction (0.04-0.07 mg protein) was added 
to 2.9 ml of 50 raM potassium phosphate buffer, pH 7.4 
containing 0.33 mM sodium pyruvate and 80 ym NADH (final 
concentration/3 ml) in a cuvette in a Beckman DB spectro­
photometer (Beckman Instruments Ltd., Glenrothes, Fife, U.K.), 
stirred and the change in A^^q with time recorded for 1 min 
at 37°C to give the activity of free LDH. 0.2 ml of 10%
Triton X-100 was added and the change in A^^q was recorded for 
a further 1 min to measure the total LDH activity (Fig. 10). 
Occluded LDH is given as
1 - ( ^ % (Marchbanks, 1967).
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2.3.7 Protein Estimation
Precipitated protein was dissolved in 1 ml of 0.1 M 
NaOH and aliquots assayed using the Bailey (1962) modification 
of the method of Lowry et al, (1951), Bovine plasma albumin 
was used as standard (Pig. 11).
2.4 Statistical Methods
2.4.1 Wilcoxon (or Mann-Whitney) Test
Statistical significance was determined using the 
Wilcoxon (or Mann-Whitney) test (Colquhoun, 1971), a non- 
parametric test which makes no assumption about the distribution 
of the observations or about the homogeneity of variances in 
the two samples.
Observations are ranked in ascending order and each 
observation replaced by its rank before performing the test.
If the null hypothesis is true, the distribution of the sum 
of the ranks for the sample with n observations (R^) can 
be shown to have mean and standard deviation a . The
approximate standard normal deviate is calculated as
U =
a
where (mean of
a (standard deviation of R^) = ^
n = sample with n observations 
m = sample with m observations 
The rarity of the result is judged from tables of the 
standard normal distribution. A value of p less than 0.05 
was considered significant.
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Fig. 11 BSA standards were treated as described (2 ,3 .7 ) and
corrected for zero blank.
2.4.2 Linear Regression
Linear regression was used to determine whether or not
there was a relationship between the two variables, dopamine
synthesis (x) and drug-induced increase in dopamine synthesis
(y) (Colquhoun, 1971).
The test assumes that the variable y is linearly
dependant on the variable x, i.e. the points (x_, y^ )^ lie
on the line with equation y = a + gx.
The points (x^, y^) do not actually lie on any single
straight line. Random variation from this relationship
2described by a variance a , is assumed to be in the variable 
y . The variable x is assumed not to vary randomly.
Estimates a and b of a and g are obtained as
follows:-
a = intercept on y axis = y - bx
b = slope of line =
Ey. _ 2x,
where y = ■ ■ and x =n n
Cxy = Ex^y^ - nxy
2 —  2 Cxx = Ex^ - nx
n = number of observations.
2
a , a variance of the points about the line y = a + bx is 
estimated by
,2 ^ 1 (Cxy)"\   2 ^-2
n — 2 ^Cyy - ^ where Cyy = Ey^^ -
Testing the Slope in Regression
This parametric method tests the null hypothesis that 
the slope of the line y = a + gx is equal to zero, i.e.
there is no correlation between x and y.
The test statistic used to measure the deviation of 
g from zero is
' • V?
The value of t is obtained from tables of Student's t 
distribution with n - 2 degrees of freedom.
Ill RESULTS
RESULTS
3.1 Characterisation of Rat Brain Regions
The weight of the seven brain regions was determined and 
agreed with those obtained by others (Table 4). The 
hypothalamic catecholamine concentration (dopamine 0.28 +_ 0.08 
yg/g protein; noradrenaline 1.53 + 0,47 %g/g protein; means 
+ S.D. of 7 preparations) and striatal catecholamine 
concentration (dopamine 1.89, 2.23 ug/g protein; noradrenaline 
0.08, 0.26 yg/g protein), was determined and was in agreement 
with reported mammalian hypothalamic (Table 5) and striatal 
(Table 6) values. These results suggest that these regions 
have been correctly identified.
3.2 Oxidative Deamination of Dopamine
As Horst and Spirt (1974) showed that 10“^M TRH stimulated 
release of dopamine from striatal synaptosomes, this con­
centration of peptide was used in these studies.
In general, neither MIH (10"^) nor TRH (10”^M) altered 
monoamine oxidase activity in tissue slices from cerebellum 
(Table 7), cortex plus striatum region (Table 8) or medulla- 
pons (Table 9). However, due to variable results and large 
standard deviations, it was not possible to decide whether or 
not peptides at this concentration had an effect on monoamine 
oxidase activity in tissue slices. Thus it was decided to 
use sucrose homogenates.
Chromatographic Studies
Chromatographic analysis showed that DOPAC and an 
unidentified dopamine metabolite with R^ value greater than
Tablé 4 Characterisation of Rat Brain Regions
Brain regions from the number of animals indicated were 
weighed. Results are expressed as a percentage of total 
brain weigfit and are means 8 .D.
A - Data of Glowinski and Iversen C-1966)
B - Data of Holtzman (1974)
C - Data of She.llenberger and Gordon (1971)
Some portions of the cortex are lost.
Midbrain includes thalamus and hypothalamus.
Brain region
% of total brain weight
This work 
n = 5
A
n = 20
B
n = 60
C
n = 14
Cortex 42.3 + 2.1 43.9 + 3.2 56.0 + 4.2 22.4 + 3.1
Medulla-pons 18.8 + 1.2 13.8 + 1.3 16.7 + 1.5 18.8 -f- 1.9
Cerebellum 13.9 + 2.4 14.6 + 1.2 - 24.8 + 3.7
Striatum 11.6 + 1.5 5.6 + 0.9 4.8 + 0.5 11,8 + 2.8
Hippocampus 6.7 + 0.8 8.2 + 1.2 - —
Midbrain 3.2 + 0.6 8.0 + 0.5 14.9 + 1.9 22.3 + 2.4
Hypothalamus 3.5 + 0.4 6.0 + 0.8 7.6 + 0.8
Total weight 1609 1832 1452 1258of brain (mg)
Table 5 Hypothalamic Catecholaminé Content
The hypothalamic catecholamine content expressed as ug/g
are means + S.D, with the number of determinations in parentheses
Author Dopamine ug/g + S,D
Noradrenaline 
ug/g + S.D.
Coyle and Henry 
(1973)
Friedman et al 
(1973)
Glowinski and 
Iversen (.1966)
Holtzman (1974)
Metcalf (1974)
Shellenberger (1971)
0.58 + 0.10 (5)
0,32 + 0.03 (6) 
0.26 + 0.02 (15)
1.96 + 0.10 (5) 
1.84 + 0.02 (8)
1,79 + 0.10 (6)
1.37 + 0.05 (60) 
1.61 + 0.16 (9)
1.07 + 0.11 (15)
Tablé 6 ' Striatal Catécholamihé Content
The striatal catecholamine content expressed as ug/g 
are means jn 8.D. with the number of determinations 
in parentheses.
Author Dopamine ug/g + S.D.
Noradrenaline 
ug/g + S.D.
Coyle and Henry 
(1973) 8.07 + 0.92 (5) 0.35 + 0.2 (5)
Friedman et al 
(1973) 4.23 + 0.05 (8) -
Glowinski and 
Iversen (1966) - 0.25 + 0.03 (6)
Gordon and 
Shellenberger 
(1974)
5.47 + 1.87 (12) 0.32 + 0.12 (12)
Holtzman (1974) 16.78 + 0.39 (60) -
Metcalf (1974) 3.80 + 0.36 (5) 0.06 + 0.01 (5)
Shellenberger
(1971) 11.50 + 0.43 (15) 0.12 + 0.01 (15)
Shellenberger and 
Gordon (1971) 7.11 + 1.62 (14) 0,30 + 0.09 (14)
Tablés 7 - 9 Effect of MIH and TRH oh Monoamine Oxidase
Activity in Tissue Slices
Tissue slices (5.8 - 20 mg protein) were incubated for 
30 min in 1 ml of phosphate-saline with 0,2 yCi of [^^c] 
dopamine (final concentration 3.85 yM) in the presence or 
absence of peptide as shown.
Results are expressed as pmol/min/mg protein and are 
means + S.D. for the number of determinations in parentheses 
Each experiment represents the results from a separate 
preparation of brain slices from 2-6 rats.
*significantly greater then control p < 0.05.
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that of DOPAC were the main products formed when striatal 
homogenates were incubated with [^^C] dopamine (Table 10).
This unknown compound did not cochromatograph with the main 
dopamine metabolites EVA, DOPET or 3MT. However, the 
unknown compound has the same value as DOBA, the
decarboxylation product of DOPAC. Further studies are needed 
to identify the unknown compound.
Neither MIH nor TRH appeared to stimulate monoamine 
oxidase activity (Table 11) or alter the ratio of unknown 
compound to DOPAC formed. However, as less than 50% of counts 
added initially were recovered, it is not possible to place 
too much reliance on this result.
The effect of MIH and TRH on monoamine oxidase activity 
in four regions of the brain is shown in Table 12. The 
peptides did not alter the rate of deamination of dopamine in 
medulla-pons and cerebellum. As the lack of any effect might 
be due to degradation of peptide, a second addition of 
peptide was made after 15 min. A second addition of TRH 
stimulated monoamine oxidase activity in the cortex. The 
addition of TRH inhibited monoamine oxidase activity in the 
’rest' of the brain. However, a second addition of TRH give an 
activity that was not significantly different from the control 
value.
3.3 Biosynthesis of Dopamine 
Preliminary Studies
Chromatographic analysis showed that dopamine was the 
major product formed when striatal homogenates were incubated
Tablé 10 ^ o p A C v&luéé of Métabolites of Dopamine
Striatal homogenates (1.5-2,0 mg protein) were incubated in 
0.28 M phosphate buffer for 30 min with 0.2 yCi of [^^c] 
dopamine (final concentration 12.8 yM). Ethyl acetate 
extracts were chromatographed on silica gel sheets together 
with the following standards: dopamine, DOPAC, HVA, 3MT
and DOPET. The solvent system used was the organic phase 
of chloroform : acetic acid : H^O (2 : 2 : 1 by volume). 
Results expressed as Rj^ q pAC ^^^^es
_ distance migrated from origin_________
distance migrated from origin by DOPAC
Dopamine Metabolite ^DOPAC value
HVA 1 .8 + 0 .1 (9)
DOBA 1 .2 + 0 0 (4)
Unknown compound 1 .2 + 0 .1 (11)
DOPAC 1 .0
DOPET 0 .8 + 0 .1 (9)
3MT 0 .2 + 0 .0 (8)
Dopamine 0
Table 11 Chromatographic Analysis of Products Formed by 
Striatal Sucrose Homogenates Incubated with 
r^ ^c] Dopamine
Sucrose homogenates (1.5-2.0 mg protein) were incubated in 0.28 M 
phosphate buffer for 30 min with 0.2 yCi of dopamine (final
concentration 12.8 PM) in the presence or absence of peptide as 
shown. The reaction was stopped by the addition of acetone :
0.1 M HCl ( 9 : 1  v/v). Protein was removed and samples dried 
down in vacuo. The residues were extracted with acetone :
0.1 M HCl (9 : 1 v/v) and chromatographed on silica gel sheets 
using the solvent system of the organic phase of chloroform : 
acetic acid : H^O ( 2 : 2 : 1  volume). The radioactive spots 
were scraped off the chromatograms and radioactivity 
determined by liquid scintillation counting. Results are 
expressed as a percentage of counts recovered.
Sample % counts Totalcounts
%Unknown
compound
+DOPAC
Unknown
compound
DOPAC
No peptide
Unknown
compound
DOPAC
Dopamine
7.7 
6.1 
86 .2
35,101 13.8 1.3
Unknown
compound
DOPAC
Dopamine
3.7
4.9
91.4
38,522 8.6 0.8
MIH 10"^M
Unknown
compound
DOPAC
Dopamine
7.0
5.8
87.2
47,320 12 .8 1.2
Unknown
compound
DOPAC
Dopamine
4.8
5.2
90.1
28,897 9.9 0.9
TRH 10"^M
Unknown
compound
DOPAC
Dopamine
5.1
4.7
90.2
44,298 9.8 1.1
Unknown
compound
DOPAC
Donamine
7.5 
7.1 
85 .4
70,506 14.6 1.1
Tablé 12 Effect of MIH. and TRE oh Monoamine Oxidase 
Activity in Sucrose Homogenates
Sucrose homogenates (1.5-2.0 mg protein) were incubated in 
0.28 M phosphate buffer for 30 min with 0.2 yCi of [^^c] 
dopamine (final concentration 12.8 yM) in the presence or 
absence of peptide as shown. Second additions of peptide 
were made after 15 min,'Rest'-portion of brain remaining after 
the medulla-pons, cortex and cerebellum have been removed. 
Results from a single preparation are expressed as pmol/min/mg 
protein and are means + S.D, for the number of determinations 
in parentheses.
* significantly greater than control p < 0.05 
**significantly less than control p < 0.05
Additions
Monoamine oxidase activity pmol/min/mg S.D.
Medulla-pons Cortex Cerebellum 'Rest'
None 3.56+0,26(4) 2.97+0.15(4) 2.63+0.58(4) 3.65+0.19(4)
MIH
10"4m x  1 3.74+0.22(4) 2.82+0.25(4) 2.71+0.43(4) 3.71+0.20(4)
MIH 
10-4MX2 4.00+0,58(4) 3,14+0.25(4) 3.43+0.15(4)
TRH 
10“%  X 1 3.77+0,43(4) 3.24+0.26(3) 2.69+^0,27(4) 3^33+0.11(4)
TRH 
10”4m x  2 3,79+0.50(4)
*
3.30+0.31(4) - 3.56+0.10(4)
with [^^Cj tyrosine. Trace amounts of DOPAC were formed 
(Fig. 12). No significant difference was seen in chromato­
graphic maps when either MIH (10"^M final concentration) or 
TRH (10"^M final concentration) was added to the incubation.
The rate of dopamine synthesis by sucrose homogenates 
increases with time for at least 30 min (Fig. 13) and with 
protein to at least 1 mg (Fig. 14). As shown in Table 13, 
neither MIH (10"^M final concentration) nor TRH (10”^M final 
concentration) had any effect on the rate of conversion of 
[^^C] tyrosine to [^^c] dopamine.
These results suggested that the method was reproducible 
and that it was worthwhile to try to use a crude synaptosomal 
preparation to study the effect of MIH and TRH on the bio­
synthesis of dopamine. Further, this preparation may have less 
peptidase activity than sucrose homogenates as the fraction 
has been removed (Griffiths et al, 1975; 1976).
Studies with Striatal Pg Fractions
Electron micrographs of the striatal Pg fraction are 
shown in Figs. 15-17. In Fig. 15, particles, about 1 ym 
diameter, bound by a single membrane and containing mitochondria, 
synaptic vesicles and vacuoles, are visible. High-power 
electron micrographs of synaptosomes in the preparation are 
presented in Figs. 16 and 17. The limiting membrane, 
mitochondria, synaptic vesicles (about 40 nm diameter) and 
vacuoles are clearly visible (Fig. 16). The synaptic cleft 
and postsynaptic membrane are identifiable constituents of 
the synaptosome shown in Fig. 17.
The percentage of occluded lactate dehydrogenase of nine 
preparations was 85.4 + 4% (mean + S.D.) in agreement with
Chromatographic Analysis of Products Formed by Striatal
A %
Homogenates Incubated with [ C J tyrosine
^^C-DOPAC
&
14C-dopamine
Fig 12
Sucrose homogenates (2 mg protein) were incubated in 0.28 M 
phosphate buffer for 30 min with 1 y Ci of [^^C] tyrosine 
(6.86 y M) . Eluates from alumina columns were dried down in 
vacuo and the residues taken up in acetone: 0.1 M HCl (9 :iv/v) 
Extracts were chomatographed in two dimensions on silica gel 
sheets together with the following standards:- tyrosine, 
dopamine, DOPAC and HVA. The solvent systems used were:- 
1st dimension - the organic phase of chloroform:acetic acid: 
HgO (2 : 2 : 1 by volume)
2nd dimension - butan-l-ol: pyridine : ace tic acid:HgO 
(15 : 2 : 3 : 5 by volume).
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Time Course of Dopamine Synthesis by Sucrose Homogenates
E
I
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Time (min)
Fig. 13. Sucrose homogenates (2 mg protein) were incubated in 0.28 M phosphate 
buffer with 1 fjCi of [  c] tyrosine (final concentration 6.86 wM) for the 
times shown. Dopamine synthesis is expressed in pmol/mg.
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Effect of Tissue Concentration on Dopamine Synthesis
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mg protein
Fig. 14. Sucrose homogenates (0 .5  -  5 .0  mg protein) were incubated in
0.28 M phosphate buffer with 1 uCi of tyrosine (final concentration
6.86 l^A/ f^or 30 min. Dopamine synthesis is expressed in pmol/min.
Table 13 Effect of MIH and TRH bn Dopamine Synttiesis 
by. Sucrose Homo'genates
0,1 ml of sucrose homogenate C2 mg protein) was incubated 
for 30 min with 1 jiCi of [^^Cj tyrosine (final concentration
6.86 yM) in 0,28 M phosphate buffer containing pargyline 
(final concentration 0,4 raM) in the presence or absence of 
peptide as shown.
Results are expressed as pmol/min/mg protein and are 
means _+ 8 ,D. of four determinations from a single 
homogenate.
Additions
Dopamine 
pmol/min/mg + S,D.
None
MIH 10"^M 
TRH lO'^M
1.02 + 0,10 (4) 
0.88 +0,08 (4) 
0.99 + 0,05 (4)
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Fig. 15. Electron micrograph of the P^  fraction. Several synaptosomal 
profiles (arrows identified by 5) are seen containing mitochondria, 
synaptic vesicles and vacuoles.
(x 12,500)
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Fig, 16. Electron micrograph demonstrating the ultrastructure of a 
single synoptosome from the specimen shown in Fig. 15. The 
limiting membrane, four vacuoles (V), two mitochondria (m) 
and many synaptic vesicles are clearly visible.
(x 47,000)
» sm _'
Fig. 17. Electron micrograph of a synoptosome showing the 
synaptic cleft (arrow) and post synaptic membrane (psm). 
(x 60,000)
the value of 80% obtained by Heaton and Bachelard (1973) for 
cortical synaptosomes. Further, Pg fractions formed dopamine 
from tyrosine without the need of exogenous cofactors. Tyrosine 
hydroxylase activities (0.4 - 1.8 pmol/min/mg) were in 
agreement with literature values (Table 14).
These results suggested that a useful preparation for 
studying dopamine synthesis had been obtained.
The rate of dopamine synthesis by the Pg fraction increased
with time for at least 30 min (Fig. 18) and with protein to at
least 0.68 mg (Fig. 19). Incubations routinely were for 20 min
and contained 0.40-0.65 mg protein.
As calcium stimulated tyrosine hydroxylase isolated from 
rat striatum (Gutman and Segal, 1973), the effect of calcium 
on dopamine synthesis was examined. Addition of 0.85 mM 
calcium chloride caused a 30% increase in the rate of dopamine 
synthesis by the Pg fraction (Table 15). Neither MIH (10"^M) 
nor TRH (lOT^M) altered the rate of dopamine synthesis. Further, 
neither peptide significantly stimulated the rate of dopamine 
synthesis in the presence of 0.85 mM calcium chloride (Table 15). 
Modification of Dopamine Synthesis Assay
As only approximately 1,000 counts per sample were being 
recovered, the present assay required modification. Therefore, 
the amount of non-radioactive tyrosine added to the incubation 
was reduced, giving a final concentration of tyrosine of 1.07 yM 
instead of 18.4 yM. This modification caused a five fold 
increase in the number of counts converted to dopamine.
Effect of Calcium on Dopamine Synthesis at Reduced Concentrations 
of Tyrosine
Addition of calcium did not significantly increase the rate 
of dopamine synthesis at reduced concentrations of tyrosine
Table 14 Tyrosine Hydroxylase Activity in
Striatal Fractions
Author
Tyrosine Hydroxylase Activity 
pmol/min/mg
Goldstein et al, (1976) 0.42 + 0.04
Iversen et al.(1976) 0.105 S.D. not given
Kapatos and Zigmond 
(1977) 11.65 + 0.04
Karobath (1971) 5.19 + 3.60
Katz et al. (1976) 11.0 S.D. not given
Kuczenski (1975b) 0.55 + 0.04
Patrick et al (1975) 0.17 + 0.01
Time Course of Dopamine Synthesis by the Striatal20
Po Fraction
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Fig. 18. 0.1 ml of striatal Pg fraction (0.47 mg protein)
was incubated in Tris-saline with 1 yCi of tyrosine
(final concentration 1.07 \iM) for the times shown. Dopamine 
synthesis is expressed in pmol/mg protein. No significant 
difference in the time course was observed when synaptosomes 
were incubated with 18.4 yM tyrosine.
Effect of Tissue Concentration bn Dopamine
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Fig. 19. 0.1 ml of striatal Pg fraction (0.02-0.68 mg
protein) was incubated in Tris-saline with 1 pCi of [^H ] 
tyrosine (final concentration 18.4 yM) for 20 min. 
Dopamine synthesis is expressed in pmol/min.
Table 15 Effect of MIH and TRH on Dopamine Synthesis
by the Striatal Pg Fraction
0.1 ml of a striatal Pg fraction (0.40 rag protein) was 
incubated for 20 min in Tris-saline with 1 yCi of [ h^] 
tyrosine (final concentration 18.4 yM) in the presence 
or absence of peptide as shown.
Results are expressed as pmol/min/mg protein and are means 
_+ S.D. of four determinations from one P^ preparation.
^significantly greater than in the absence of 0.85 mM 
calcium chloride p < 0.05.
Additions Dopamine pmol/min/mg + S.D.
None
MIH 10"^M 
TRH 10“^M
no calcium chloride 
0.62 + 0.14 (4) 
0.63+0.05 (4) 
0.59 + 0.16 (4)
0.85 mM calcium chloride 
0.81 + 0.11 (4)
*0.82 + 0.12 (4)
*0.85 + 0.08 (4)
(Table 16).
Effect of Peptides bn Dopamlhe Synthesis at Reduced 
Concentrations of Tyrosine
Neither MIH (10"^M) nor TRH (10~^M) altered the rate of 
conversion of [^ H ] tyrosine to [^ H ] dopamine in the presence 
of 1.70 mM calcium chloride (Table 17),
MIH and TRH have been shown to have behavioural effects 
similar to those of amphetamine (Cohn et al, 1975; North et al, 
1973). Thus it was of importance to determine whether or not 
amphetamine and tyramine, a drug with effects similar to those 
of amphetamine, could stimulate dopamine synthesis under these 
conditions, as a drug-induced stimulation of dopamine synthesis 
could increase the concentration of dopamine in the synaptic 
cleft and thus lead to the behavioural effects. Tyramine, however, 
inhibited dopamine synthesis, 50% inhibition occurring at 3.3 x 
10 ^M (Table 18). The effect of amphetamine on dopamine 
synthesis under these conditions was not determined as its 
effect on catecholamine metabolism (release of catecholamines 
from peripheral and central nerve endings) is thought to be 
similar to that of tyramine (Raiteri and Levi, 1978).
Effect of Drugs on Dopamine Synthesis in the Presence of EDTA 
Kuczenski (1975b) showed that tyramine and amphetamine 
could stimulate dopamine synthesis in synaptosomes incubated 
in phosphate buffered saline containing 2 mM EDTA. It was 
thus important to check that this stimulation could be achieved 
in Tris-saline containing 2 mM EDTA and to determine whether 
or not MIH and TRH could stimulate dopamine synthesis under 
these conditions.
The stimulatory effect of tyramine and amphetamine on 
dopamine synthesis was confirmed in Tris-saline containing
Table 16 Effect of Calcium on Dopamine Synthesis
0,1 ml of striatal Pg fraction (0.54 mg protein) was 
incubated for 25 min with 1 yCi of {^h] tyrosine (final 
concentration 1.07 yM) in Tris-saline containing calcium 
chloride as shown.
Results from a single preparation are expressed as pmol/min/mg 
protein and are means + S.D, for the number of determinations 
in parentheses,
Additions
Dopamine 
pmol/min/mg + S.D.
None
Calcium chloride
1 mM
Calcium chloride
2 mM
0.50+0.04 (3)
%
0.55 + 0.01 (3) 
0.53 + 0,02 (3)
Table 17 Effect of MIH and TRH on Dopamine Synthesis
0.1 ml of striatal fraction (0.61 mg protein) was 
incubated for 20 min with I pCi of [^h ] tyrosine (final 
concentration 1.07 yM) in Tris-saline containing 1.70 mM 
calcium chloride in the presence or absence of peptide as 
shown.
Results are expressed as pmol/min/mg protein and are means 
+ S.D. of four determinations from one P^ preparation.
Additions
Dopamine 
pmol/min/mg + S.D.
None
MIH 10"^M 
TRH 10“^M
0.57 + 0.01 (4) 
0.54 + 0.04 (4) 
0.55 + 0.08 (4)
Table 18 Effect of Tyramine on Dopamine Synthesis
0.1 ml of striatal Pg fraction (0.7 mg protein) was 
preincubated for 10 min in Tris-saline containing 1.70 mM 
calcium chloride in the presence or absence of tyramine 
as shown, then incubated for 20 min with 1 pCi of ] 
tyrosine (final concentration 1.07 yM).
Results from a single preparation are expressed as 
pmol/min/mg protein.
3.3 3.3 6.7 3.3 3.3
Tyramine (M) None
X lQ-7 X 10-G X 10“® X 10“® X 10“4
Dopamine
pmol/min/mg
0.36 0.33 0.27 0.21 0.18 0.20
- - -  - ........
2 mM EDTA. Preliminary studies (Table 19, experiments 1-5) 
showed that maximum stimulation of dopamine synthesis by 
amphetamine and tyramine occurred over the range 10”®-10“^M 
and suggested that 10”^M peptide could stimulate dopamine 
synthesis. In a further experiment (Table 19, experiment 6) 
both TRH (10”^M) and amphetamine (10“^M) independently 
stimulated dopamine synthesis but in two subsequent experiments 
(Table 19, experiments 7 and 8), TRH (10“^M) did not influence 
dopamine when amphetamine (10“®M and 10”^M) stimulated dopamine 
synthesis. In the next experiment (Table 19, experiment 9) 
amphetamine (10~^M) did not influence dopamine synthesis.
TRH (10”^M), however, inhibited dopamine synthesis under these 
conditions, TRH (10“^M) did not interfere with amphetamine 
(10“^) induced stimulation of dopamine synthesis (Table 19, 
experiments 6 and 7).
However, more detailed study revealed that the magnitude 
of the stimulation of dopamine synthesis by amphetamine (10“^M) 
(Fig. 20) and tyramine (10“^M) (Fig. 21) varied inversely with 
the basal rate of dopamine synthesis (0.55 + 0.10 (4) - 
1.79 +_ 0.11 (4) pmol/min/mg protein: data from the 9 separate
experiments in Table 19). A significant negative correlation 
(p < 0.05) between amphetamine (10“^M) induced stimulation 
and the basal rate of dopamine synthesis was found (Fig. 20)
No such correlation could be found for the data with 
TRH (10”^M) (Fig. 22). This suggested that the mechanism 
of action of this peptide was different from that of the 
sympathomimetic amines amphetamine and tyramine. The results
/ y
Table 19 Effect of Drugs on Dopamine Synthesis
0.1 ml of striatal fraction (0.4 - 0.7 rag protein)
was preincubated for 10 min in Tris-saline containing 2 mM 
EDTA in the presence or absence of drug as shown then incubated 
for 20 min with 1 pCi of [®H] tyrosine (final concentration 
1.07 yM). Results are expressed as pmol/min/mg protein and
are means S.D. for the number of determinations in parentheses
Each separate experiment represents data from a single 
preparation of 3 rats.
* significantly greater than control P < 0.05 
** significantly less than control P < 0.05
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of experiments in which synaptosomes were not preincubated 
with TRH were not very different from those in which
preincubation with TRH (10“^M) occurred (Fig. 22). Thus 
it was unlikely that the difference in action between TRH and 
amphetamine and tyramine was due to degradation of peptide.
Possible Reason for Variation in Basal Dopamine Synthesis Rate 
It bas been suggested that there are two distinct storage 
pools of dopamine in dopaminergic nerve terminals (De Belleroche 
et al, 1976; Doteuchi et al, 1974; Javoy and Glowinski, 1971; 
Kuczenski, 1975b). According to tbe model of Kuczenski (1975b), 
these pools are a large storage pool and a smaller pool
functional in the regulation of tyrosine hydroxylase. The
activity of tyrosine hydroxylase may then reflect the size 
of this regulatory dopamine pool. If the concentration of 
dopamine in the inhibitory pool is high, then tyrosine
hydroxylase activity will be low. Thus releasing agents,
for example amphetamine and tyramine, may be able to stimulate 
dopamine synthesis by releasing tyrosine hydroxylase from 
feedback inhibition. Conversely, if the inhibitory pool is 
depleted, tyrosine hydroxylase activity will be high and 
unable to be increased further as releasing agents cannot act.
Attempt to Alter the Size of the Inhibitory Dopamine Pool
As the variation in dopamine synthesis may be due to the 
size of an inhibitory dopamine pool, an attempt was made to 
alter the dopamine content of the P^ fraction (Table 20).
The Pg fraction was incubated in Tris-saline containing 
10~^M dopamine to load the inhibitory pool. After centrifugatiot
Table 20 Effect of Preincubation with. Dopamine 
on Dopamine Synthesis
0.5 ml of 8^ fraction was incubated for 20 min with 1 ml 
of Tris-saline containing 0.4 mM pargyline, 120 yM EDTA 
and 1.65 mM ascorbic acid in the presence or absence of 
dopamine. Preincubation was terminated by centrifugation 
at 17,000 g for 15 min. The Pg fractions were re­
suspended and incubated as described in legend for Table 19 
Results are expressed as pmol/min/mg protein and are 
means +. S.D. for three determinations from one Pg 
preparation.
^significantly less than incubation in the absence of 
dopamine p < 0.05 .
Additions Dopamine pmol/min/mg + S.D.
None
Dopamine 10"^M
1.84 + 0.08 (3) 
*0.82 +0.07 (3)
«8
and resuspension, dopamine synthesis was measured. An 
identical sample was first incubated in Tris-saline without 
dopamine to deplete the inhibitory dopamine pool. Then 
dopamine synthesis in the dopamine depleted fraction was 
measured,
In agreement with the above predictions, incubation with 
dopamine caused a greater than 50% inhibition of the conversion 
of [^ hJ tyrosine to [^ h ] dopamine,(Table 20).
As the stimulation of tyrosine hydroxylase by amphetamine 
and tyramine occurs as a result of stimulation of release of 
dopamine (Kuczenski, 1975b) and the effect observed on tyrosine 
hydroxylase may depend on the size of an inhibitory dopamine 
pool (Kuczenski, 1975b),it was decided to examine the effect 
of amphetamine, MIH and TRH directly on release. Further, 
it was important to determine whether or not differences in 
the effects of these drugs on dopamine synthesis would be 
reflected in differences in dopamine release.
3.4 Release of Dopamine
Uptake of dopamine by striatal Pg fractions increased 
approximately thirty fold over the range 2.5 x 10”^M -
2.5 X 10"^M dopamine (Table 21). Therefore 2 x 10~^M dopamine
was used to load P^ fractions. Eitan and Hershkowitz (1977)
reported that 25.6 pmoles of dopamine were taken up per mg
—8of protein when fractions were loaded with 7 x 10“ M
dopamine. The data of Table 21 is in agreement with this 
value.
—8When the P^ fraction was loaded with 2 x 10 m dopamine ,
Table 21 Uptake of [^h ] Dopamine by Striatal Pp Fract ions
0.2 ml of S^ fraction was incubated for 10 min in 3.8 ml 
of Tris-saline with the concentration of [^h ] dopamine shown 
Results are expressed as pmol/mg protein and are means + S.D 
for the number of separate experiments in parentheses.
Dopamine concentration (M) Uptake pmol/mg + S.D.
2.5 X 10“® 3.30 + 0.27 (4)
2 . 0  X 1 0 “ ® 9.63 + 3.64 (20)
2.5 X 10“® 16.60 + 4.86 (6)
2.0 X 10“? 73.65; 76.00
2.5 X 10“? 119.00 +5.89 (4)
wu
th.e rate of release was linear for at least 2 rain in the 
absence of araphetaraine (Fig. 23). Amphetamine stimulated 
release over the time interval O-rS min, the greatest stimulation 
being observed at 1 min. Therefore the effect of drugs on 
a 2 min release of dopamine was studied.
Eitan and Hershkowitz (1977) reported that 1.3 and 3.0 
(data from 2 striatal Pg fractions) pmol of dopamine were 
released per min per mg of protein in the presence of 1,3 mM 
calcium chloride. In this thesis 0,69 _+ 0.43 (mean + S.D. 
of 14 striatal Pg fractions) and 0.62 + 0.26 (mean + S.D. of 
11 striatal Pg fractions) pmol of dopamine were released per 
min per mg of protein in the presence of 1.25 mM calcium 
chloride and 2 mM EDTA respectively. This suggested that a 
suitable preparation for studying dopamine release had been 
obtained.
In one experiment (Fig. 24), the Pg fraction was loaded 
with 2 X 10“ M dopamine. The time course of dopamine release 
in the presence of 2 raM EDTA or 1.25 mM calcium chloride over 
a period of 1 h is shown. Release of dopamine was observed 
to be biphasic, a quick release occurring followed by a slower 
release. Incubation at 0°C for 1 h did not increase the blank 
value.
Effect of Drugs on Release of Dopamine
Preliminary studies indicated that amphetamine, MIH and 
TRH stimulated release of dopamine from striatal P^ fractions 
in the presence of 1.25 mM calcium chloride. Maximum stim­
ulation of release with amphetamine (400%) occurred at 10“^M
Time Course of Release of Dopamine from the
Striatal Pp Fraction
40
Amphetamine
10-4m
30
No drug
^ 20+
10
1 20 3 4 5
Time (min)
Tig.23 The S^ fraction was loaded for 10 min with [^h] 
dopamine (final concentration 2 x 10”®M). 0.1 ml of
resuspended pellet was added to 2.9 ml of saline 
containing 1.25 mM calcium chloride in the presence or 
absence of amphetamine and release of dopamine allowed to 
proceed for 0-5 min.
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Time Course of Release of Dopamine
calcium chloride 
1.25 mM
from the Striatal Pm Fraction
40
EDTA 
2 mM
30
+ 20
10
O 10 20 30 40 50 60
Time (min)
Pig. 24 The 3^ fraction was loaded for 20 min with [^H] 
dopamine (final concentration 2 x 10"^M). 0,1 ml of resuspended
pellet was added to 2.9 ml of saline containing either 1.25 mM 
calcium chloride or 2 mM EDTA and release of dopamine allowed 
to proceed for 0-60 min.
(Table 22), while the greatest stimulation observed with the 
hypothalamic peptides, MIH (130%) (Table 23) and TRH (110%)
_  o
(Table 24) was at 10" M„ Thus these drug concentrations 
were used in all experiments.
The amount of dopamine taken up by Pg fractions varied from 
preparation to preparation as did the ratio of S/S + P and 
the % -.stimulation. , However, a drug-induced stimulation 
of release was consistently observed.
Influence of Calcium oh Drug-In due ed Release of 
Dopamine from Striatal Pp Fractions
Kuczenski (1975b) examined the effect of amphetamine
and tyramine on dopamine synthesis in the presence of EDTA at
pH 6.6, while Patrick and Barchas (.1976) examined the effect
of tyramine on dopamine synthesis in the presence of calcium
chloride at pH 7.2, Thus it was necessary to determine the
effect of calcium on drug-induced release at both pH's,
— 4At pH 7.2, amphetamine (10 M) stimulated release of 
dopamine in the presence of calcium chloride (118-129%)
(Table 25, experiments 1 and 2) and also in the presence of 
EDTA (74%) (Table 28, experiment 4). MIH (10"^M) (Table 26, 
experiments 1-4) and TRH (10"^M) (Table 27, experiments 1-4) 
stimulated release of dopamine in the presence of calcium 
by 14-48% and 15-59% respectively, but the stimulation was less 
than that induced by amphetamine (118-129%). Unlike 
amphetamine neither MIH (10"^M) (Table 29, experiment 4) nor 
TRH (10“^M) (Table 30, experiment 5) stimulated release of 
dopamine in the presence of EDTA,
Table 22 Effect of Amphetamine on Release of
Dopamine from the Striatal Pp Traction
The fraction was loaded for 10 min with [^h J dopamine
_o
(final concentration 2 x 10 M). 0.2 ml of resuspended
pellet was added to 2.8 ml of Tris-saline containing 1.25 mM 
calcium chloride in the presence or absence of amphetamine 
and release of dopamine allowed to proceed for 2 rain.
S/S + P values are corrected for a 0^ blank of 37.6%.
cpm S/S+P
%
%
Additions Supernatant Supernatant (S) + 
Pellet (P)
Stimulation
None 17,466 .0 
13,108.5
39,424.5
27,873.0
6.7
9.4
-
Amphetamine
ICT^M 14,583.0 32,016.0 7.9 -2
10”^M 16,206.0 27,725.0 20.9 +159
10“^M 23,391.0 38,733.5 22.8 +183
10"^M 35,625.0 45,568.5 40.6 +404
10"^M 20,106.0 31,516 .5 26.2 +225
Table 23 Effect of MIH on Release of Dopamine from
the Striatal Pp Fraction
The S^ fraction was loaded for 10 rain with [^h ] dopamine
—  R
(final concentration 2 x 10" M). 0.1 ml of resnspended
pellet was added to 2.9 ml of Tris-saline containing
1.25 mM calcium chloride in the presence or absence of MIH 
and release of dopamine allowed to proceed for 2 min.
S/S + P values are corrected for a 0° blank of 45%.
Additions
cpm S/S+P
%
%
StimulationSupernatant Supernatant (S) + Pellet (P)
None 8.457.0
7.737.0
16.521.0
14.619.0
6.2
7.9
-
MIH 10"?M 7,672.5 14,495.0 7.9 +12
10"^M 8,263.5 15,986.5 6.7 - 5
10"^M 7,545.0 13,302.5 11.7 +66
10"^M 7,839.0 14,226 .0 10.1 +43
10"^M 7,782.0 12,712.5 16.2 +130
Table 24 Effect of TRH on Release of Dopamine from
the Striatal Pp fraction
The S^ fraction was loaded for 10 min with [^h ] dopamine 
(final concentration 2 x 10”^M). 0.1 ml of resuspended
pellet was added to 2.9 ml of Tris-saline containing 1.25 mM 
calcium chloride in the presence or absence of TRH and 
release of dopamine allowed to proceed for 2 min. S / S + P  
values are corrected for a 0° blank of 46%.
Additions
cpm S/S+P
%
%
StimulationSupernatant Supernatant (S) + Pellet (P)
None 7,147.5
7,485.0
12.956.5
12.753.5
8.8
12.3 -
TRH 10"?M 8,020.5 14,448.0 9.1 —14
10“^M 7.885.5 13,011.0 14.2 + 35
10“^M 8,155.5 13,388.5 14.5 + 37
10"^M 8,295.0 13,195.5 16.5 +56
10"^M 8,721.0 12,752.0 22.0 +109
Tables 25-27 Effect of Drugs on Release of Dopamine from
Striatal Pp Fractions in the Presence of 
Calcium Chloride
S^ fractions were loaded for 10 min with dopamine (final
concentration 2 x 10~®M). 0.1 ml of resuspended pellet was
added to 2.9 ml of Tris-saline (pH 6.6 or pH 7.2) containing
1.25 mM calcium chloride and release of dopamine allowed to 
proceed for 2 min. Results are means _+ S.D. of four 
determinations from a single preparation.
* significantly greater than control P < 0.05.
Tables 28-30 Effect of Drugs on Release of Dopamine from
Striatal Pp Fractions in the Presence of EDTA
S^ fractions were loaded for 10 min with [^ H] dopamine (final
— Rconcentration 2 x 10" M). 0.1 ml of resuspended pellet was
added to 2.9 ml of Tris-saline (pH 6.6 or pH 7.2) containing 
2 mM EDTA and release of dopamine allowed to proceed for 
2 min. Results are means + S.D, of four determinations from 
a single preparation.
* significantly greater than control P < 0.05 
** significantly less than control P < 0.05
ci
-p
ci
•H
U
+->
I
u
44
0
•H
I
AO
Q
44
o
0
Ui
Ci
0
r4
0
cri
G
0
0a
•H
1
-p
0
Æa
44
O
•p
Ü
0
44
44
M
m
CM
0
r4
Eh
043
•H
P
O
r4
g
•H
Ü
I— 1
ci
O
44
O
0
0
A
0CO
0
à
0
ÆP
sn
•H
So
•H
P
Ü
ci
a
0??
N
ai ai
iD o CO
CO • • lO
P CM, CM, 00a CO + 1 + 1 +
X P 00
H wa <31 to
p
*
/—s
•w ai ai
CO 'w'
CO o O ai
p [> CM CO LOa CO CM| rH CD p 1 00
X + 1 + l CM a t> p , CM, ai
a M w H + X +1 + +a • ■ a H w Ci o
+ G: CO a
CO + ai CM
CQ * p CM
00 *
m
CO
0 /—s
CQ 0 ai ai
ci CM • en
0 CM lO 00 p a
(H p • • • Cl ci 0 CO 00
0 a CM, o, CM P 0 p CM , • ai
P X + I + 1 P ci ■a 0 p • p , CO, p
M w CM + •H •H p a + 1 + 1 +
0 a • • P p X t>
a t> Ci P 0 0 H w . •
•H P CO 00 p a a ai to
S * a) •H p p
ci E o S *a O a
o P a a
t3 P a o
•H 43 ai ai
r— 1 \—' 0 0
W iH a 1—1 <— 1
M CM Ci lO •H a w CM CO CM
-H • • • CO S u CO CM Oa O, o, 1—1 a P • CO, CM, CO
X + 1 +1 1—1 a p a +1 +1 +
M K CO ITD + 0 o X 00 lOa • • Q H œ
lO CO 0 a uo 6
p CO p 0 p CM
* 0 a *
0
0 men 0
s a p /-N
TM 0 a ai ai
1 p
O a 0 0 1—1
1—1 0 Ph ai CM p CM
CÛ ■H p P . • .
a 0 p a a 1—1 O, ai
0 C3 ci o a X + 1 + j +
•H •H P ■H M M Ci t>
P S a w a .
•H ci B HH en la CO
43 p ■H s a *
43
0
0 4-1
p
o
<! .a CO •Ha a o Po s 0
s <1 p a
0 p
0 à a
P en 0
P a •H
M al 0 P
•H a
P CO p
•H 1 a
CD 43 o G
CM 43 p •H
•a 0 p0 a ta en
P o 1-4
a % S
p
la
p
1
to
to
%
/—\
^  T|1
Vw^
O  to
s, î,
p  t>
Ci CM 
CM 
*
Ci
p
+
CO p
Tg • «
CM p  p a
a P • + 1 +1 m
a Ci t> +
+ X • •
a a rJH CO
a p  CM 1—1"— * a
CO p
a
0 •H
Ui a
a p
0 00
p p CO
a 0 CM P  CM S
p 0 P p • • • 0
a 43 a t> CO CO, lO a
•H •H 0 X + 1 +1 p p
P P a a a 00 CO +
P O •H a • ■ 0
CO P S to Ci a
a a p  p •H
s o a SQ Q
p S 43 \ a
p a 0
•H f— » 'w' x_/ Q
0 Ü W
a 1—1 CO to CM p
•H a CM • • 0
B o CM CM lO, CM
a P • + 1 +1 CM 0
a p a CM CM + Uio o X • • a
Q a a 00 CM 0
0 a P  CM 1—1
p ü 0
o a a
0
0 Ui a
(Q 0 /—s /-\ 0
a p
0 a 0
p p a
0 0 CM O  to •H
a a p • * * S
p a !> p  p to a
a X + 1 +1 CM p
0 a a a r—1 to + 0
■H a • • a
a P a
a « P  CM s
p a * <n
0
p p p
0 p o
ü
p a p
ü p ü
0 a a 0
p Ui o pp CM a ■H p
M al 0 P M
‘H S a
P CO p
*H I a
IS 43 o s 00
CM 43 1—1 ■H CM
< 0 P
0 a a a 0
P o a P
-a a  Eh 6 % aa a
P p
g
p
o
0ü
a0w0pa
0
g
a
•H
Wao
•HP
Oa
Ê
CM
al
x-\
Tg p
CM 00 LO
p
a o, o,
X +1 + 1 +
M
s
UO
1—1 
CM
t>
CO
*
a TM 'a
+
CO , to CO
CO to • Ci
p • p o, to
CO a to + 1 +- p
X CO q +
0 M a •a Ci lOa CM
0 *
p
0 'a
"Ml ■cji
0a
•H CM O î>S to • oa P • p , o, CJla a to + 1 + p
o X CM o +
43 M % to 00
p
*
COt—J
p ■Ml
P
to LO CM
P • • « CMa to p , P , P
X +1 + 1 CO
M % pp
Ci
to
p
*
+
s
p
OCû 1—1 aa o0 0 ■H
•H a p
p p a
•H S p
43 a a
43 p s•a
0
§
a
0
1
•H
P
CO
6%
ap
a
•H
a
p
CO
i
ap
0a
a
a
ft
o
p
p
o
0W
a
0
p
a
a
o
aHH
s
p
o
p
0
0
p
p
a
a
CM
0
p
•§
g
p
o
0Ü
a003
0
a
ft
0
g
a•H
03
a
o•H
p
0
a
a
ft
CM
f t !
5%
P
&
ft
CM
P
a
f t
Tji rfi
a  to
Î ,  Î ,CO 01
P  01 
CM P
p1
f t /—N /—V
+
W CO
CD CM OKJ p • • • p
f t a P  1—1 to0 X + 1 +1 103 f t a a  pa f t • •0 a  TMrH *
0 *
, a
0a Til•H ' '—"
a CMa a lO lOf t P • $ • ao f t a rH, O,a X + 1 + I 1
ft a a  P
r-n f ta P  TfCO *L__J *
/—N /—S
Tfl Tf1
p O CO
a • • 1—1p iH rH a
f t a + 1 +1 !X a  (31f t a * ■
f t to CO
03 aa oo p•H pP g aP a pT3 1 aa O a<c 1—1 p
0 p
a a ao pa  s
p
a
p
a
p
a
p
a
a
o
a
p
0 •a
a Eh
p Q
a ft
a
ft p
o 0
Q
0p 0
o a
0
0 CO03 0
a a
0 ft
p
0 0
a a
p
a
o a
p
03
a
0
p p
o p0
p a0 a
0 ft
pp CM
ft ftl
o
CO
0
rH
"a
P
lO
p
&
ft
CM
%
TJ1 Tg
to to
i
p  p  
CM CM
p
I
/-V /-\
TjH TJ1
■Tii
CO O  ISft P • aft CO rH, d. p
+ X + + 1ft ft p  o
a ft * •
oi a
a
0
CO
a /—X /—V,0 Tf1 Tfl
p
0 a
a CO to ^
p • # * a
0 ft CD CM, iH p
a X + 1 + ! 1
p ft ft CO 00
s ft • •
a P  01
ft p
o
r—?ft
CO X_/
CM
CO CO t>
P CM
ft CO o, o, CM
X + 1 + 1 +
ft ft to CO
ft • *
IS Cl
*
N /—S
Tjl T)1
v.-' —/rH
CO O  Cl
-P
ft to 1— i p P
X + 1 + ! 1ft ft 00 I>
ft * «P 1—!
p  p
a0
03 p
a p0 a
p CO p
p 1 a
p o aT3 p •HTJ 0 P<C a ft aO ftft Eh
At pH 6.6, amphetamine (10~^M) again stimulated release 
of dopamine in the presence of calcium chloride (267%)
(Table 25, experiment 3) and also in the presence of EDTA 
(.169-312%) (Table 28, experiments 1-3). MIH (10“^M) 
stimulated release of dopamine in the presence of calcium 
chloride by 85% (Table 26, experiment 5). In the presence 
of EDTA, MIH (10"^M) inhibited release of dopamine by 
31-51% (Table 29, experiments 1-3). TRH (10“^M) stimulated 
release of dopamine in the presence of calcium chloride by 
149% (Table 27, experiment 5). TRH (10"^M) did not influence 
release of dopamine in the presence of EDTA (Table 30, 
experiments 1-4).
IV DISCUSSION
Discussion
The work presented in this thesis was carried out to 
obtain biochemical support for the idea that the behavioural 
effects of the hypothalamic hormones, MIH. and TRH, are a 
consequence of an increased amount of dopamine at central 
synapses (Cohn et al, 1975; Plotnikoff and Kastin, 1976).
In vitro preparations were used to reduce the complications 
inherent in vivo studies, for example, the inability of 
peptide to penetrate the blood-brain barrier efficiently.
The work will be discussed in two main sections. Firstly, 
a critical analysis of the preparation used and secondly, 
a discussion of the effects of MIH and TRH on presynaptic 
dopaminergic mechanisms to try to relate these to the 
reported behavioural effects of the hypothalamic peptides.
4.1.1 In vitro Preparations used to Study the Effect 
of Drugs on Dopaminergic Mechanisms
As the striatum has been implicated in the control of 
locomotory activity (Lloyd and Hornykiewicz, 1975), this 
region was chosen for study.
Tissue slices have proved a popular tool for many 
biochemical investigations (Mcllwain, 1975), including the 
study of dopaminergic mechanisms (Arnold et al., 1977;
Holmes and Rutledge, 1976; Uretsky and Snodgrass, 1977). 
This preparation is less complex than an intact organ 
but it still has considerable structural integrity. As 
most of the cells are intact, it is unnecessary to fortify 
the preparation with coenzymes or cofactors. Further, in
the absence of a normal blood supply, materials normally 
exchanged with blood are exchanged with the fluid which 
surrounds or flows over the tissue. Thus the problem of 
the inability of peptide to penetrate the blood-brain 
barrier is avoided. Cut surfaces are an advantage in 
that added substrates may penetrate but a disadvantage in 
that leakage of materials out of the slice may also occur.
The structural integrity of tissue slices encouraged their 
use in this thesis. However, the variability of results 
obtained rendered the preparation unsuitable for studying 
presynaptic functions. Thus it was decided to use crude 
synaptosomal preparations.
Synaptosomes, pinched off nerve endings, may be a useful 
in vitro system for studying presynaptic function 
(Christiansen and Squires, 1974). They display many of 
the general biochemical and physiological characteristics 
associated with intact nervous tissue, for example, linear 
respiration, ATP production and maintainence of high 
potassium levels (De Belleroche and Bradford, 1973). Crude 
synaptosomal preparations (Pg fraction; Gray and Whittaker, 
1962), however, have been used by many workers for studies 
of synaptosomal properties, especially for studies of 
catecholamine metabolism (for example, Andrews et al., 1978; 
Bagchi and Smith, 1976; Cho et al., 1977; Christiansen and 
Squires, 1974; Coyle, 1972; Coyle and Snyder, 1969;
Goldstein et al., 1976; Harris et al., 1975; Holz and Coyle, 
1974; Iversen et al., 1976; Kapatos and Zigmond, 1977;
Karobath, .1971; Katz et al., 1976; Kuczenski, 1975b;
Patrick and Barcbas, 1974, 1976; Patrick et al., 1975;
Seeman and Lee, 1974; Snyder and Coyle, 1969). Crude 
synaptosomal preparations contain osmotically sensitive 
sodium, potassium and occluded lactate dehydrogenase, 
the richest source being the synaptosomal fraction (Marchbanks, 
1967). As the release of osmotically sensitive sodium, 
potassium and occluded lactate dehydrogenase had similar 
characteristics with respect to the degree of osmotic 
'shock' necessary and the action of detergents (Marchbanks,
1967), the integrity of the synaptosomal membrane is often 
assessed by measuring the activity of lactate dehydrogenase 
under iso-osmotic conditions and then again after disruption 
of the synaptosome with triton X-100 (Heaton and Bachelard,
1973; Whittaker, 1969).
Most of the tyrosine hydroxylase activity in P^ fractions 
was found to be associated with the synaptosomal fraction 
after sucrose density gradient centrifugation (Andrews et al., 
1978; Coyle, 1972). Further, Kuczenski (1975b) reported that 
when crude synaptosomes were used to synthesise dopamine the 
results were identical to those obtained using purified 
synaptosomes. Similarly Coyle and Snyder (1969) reported 
that when S^  ^ fractions were incubated with [^H] dopamine,
dopamine was taken up by synaptosomes and not by mitochondria. 
These observations suggest that it is valid to use crude 
synaptosomal preparations to study dopamine synthesis and 
release. However, as indicated by De Belleroche and Bradford 
(1973), caution is needed in the use of such a crude preparation,
as a third, of the protein present in the fraction is 
contributed by mitochondria and another third by myelin 
fragments.
In this work, electron micrographs revealed particles 
of the correct size and shape and content as synaptosomes 
(Gray and Whittaker, 1962) and measurement of occluded 
lactate dehydrogenase indicated the integrity of the 
synaptosomal membrane. Further, the Pg fraction synthesised 
dopamine and took up and released dopamine at rates comparable 
with literature values. This suggested that a useful 
preparation for studying dopaminergic mechanisms had been 
obtained.
4.1.2 Complications in the Study of the Biochemical Effects 
of Hypothalamic Hormones
The hypothalamic hormones are rapidly degraded by 
brain peptidases. Thus, if the peptide is degraded before 
it can act, no effect on dopaminergic mechanisms might 
be observed. Alternatively, if an effect is observed, 
this could be due to a degradation product of the peptide 
and not to the peptide itself. The peptidases are not 
confined to the hypothalamus but are also found in the areas 
of the central nervous system where the hypothalamic hormones 
have been detected and may have their actions (Griffiths 
et al., 1975, 1976) .
The primary mechanisms involved in the degradation of 
TRH are removal of the pyroglutamyl moiety by pyroglutamyl 
peptidase or deamidation (Marks, 1978). Histidy1-proline
amide is unstable and can be converted to hlatidyl-proline 
diketopiperazine which, has been reported to antagonise 
ethanol narcosis (Prasad et al., 1977). This suggested that 
TRH metabolites may play a part in its biological effects.
Unlike TRH, MIH was not inactivated by deamidation. Inactivation 
was achieved by cleavage of Pro-Leu and Leu-Gly-NHg bonds.
The order of peptidase action was not determined (Marks, 1978).
8ubcellular fractionation of various brain areas 
(hypothalamus, thalamus, cortex, cerebellum) indicated that 
between 56 and 91 percent of peptidase activity was present 
in supernatant fractions (Griffiths et al., 1975, 1976).
Further, the highest levels of peptidase was found in the 
27,000 g supernatant of subcellular fractions of hamster 
hypothalami. (Prasad and Peterkofsky, 1976). This suggested 
that sucrose homogenates and crude synaptosomes (S^ fraction) 
would have high peptidase activity while purified synaptosomes 
would have none. In agreement with this suggestion 
Parker et al., (1977) found that TRH was degraded by crude 
synaptosomes (Sj^  fraction) but not by synaptosomes purified 
by sucrose density gradient centrifugation.
It is improbable that degradation of MIH and TRH by 
brain peptidases is of importance in this work. Firstly, 
the Pg preparation is unlikely to have high levels of 
peptidase as the 8^ fraction has been removed. Secondly, 
peptide was not preincubated with the preparation, thus 
decreasing the possibility of degradation of peptide. Thirdly, 
second additions of peptide did not alter the rate of the
_IU#
oxidative deamination of dopamine. Thus the lack of any 
effect of MIH and TRH on the biosynthesis or oxidative 
deamination of dopamine was unlikely to be due to degradation 
of peptide. However, the possibility that degradation 
products of TRH, for example histidyl~proline diketopiperazine, 
exerted an effect on dopamine release cannot be excluded at 
present.
4.2 Effect of MIH and TRH on Presynaptic Dopaminergic 
Mechanisms
4.2.1, Effect of MIH and TRH on Inactivation of Dopamine
MIH and TRH had no effect on the oxidative deamination 
of dopamine, suggesting that inhibition of monoamine oxidase 
is unlikely to be the primary site of action of the hypo­
thalamic hormones. This agrees with the work of Breese 
et al. (1974), who reported that TRH had no effect on the 
oxidative deamination of noradrenaline in mouse brain.
However, Wirz -Justice and Lichtsteiner (1977) observed that 
while TRH inhibited monoamine oxidase in the median eminence 
of male rats, it stimulated monoamine oxidase in pro-oestrous 
female rats.
Autoradiographic analysis revealed that there were two 
products of the oxidative deamination of dopamine. One,
DOPAC, is the major metabolite of dopamine in brain (Goldstein 
et al., 1959). The other had the same R^ value as DOBA, the 
decarboxylation product of DOPAC. However, any DOBA formed 
from [ethylamine-l-^^C] dopamine would not be radiolabelled.
De Belleroche et al. (1976) have previously reported 
the formation of DOBA in synaptosomal preparations from 
sheep brain. DOBA has also been isolated from urine after 
intravenous injection of dopamine (Alton and Goodall, 1969) 
or noradrenaline (Peskar et al., 1971). In this thesis, 
roughly equal amounts of the two dopamine metabolites were 
formed; MIH and TRH did not alter the total amount of the 
two metabolites formed or the distribution of counts between 
them.
Further, MIH and TRH have been reported not to inhibit 
reuptake of catecholamines (Breese et al., 1974; Horst and 
Spirt, 1974; Tuomisto and Mannisto, 1973). Thus as MIH 
and TRH did not inhibit either the oxidative deamination 
or the reuptake of dopamine, the behavioural effects of the 
hypothalamic hormones are unlikely to be due to an inhibition 
of inactivation of catecholamines. Further, although it 
may be effective in the treatment of depression, (Kastin et al., 
1972; Prange et al., 1972) TRH may not act like the major 
known antidepressants, namely the tricyclic drugs and the 
monoamine oxidase inhibitors.
4.2.2. Effect of Drugs on Release of Dopamine
Release of catecholamines from central nerve terminals 
has only been partly characterised. In comparison, much 
more is known about release of catecholamines from the peripheral 
nervous system and the adrenal medulla.
Stimulation of the preganglionic nerve fibres of the 
adrenal medulla by acetylcholine released noradrenaline
accompanied by ATP, dopamine-g-hydroxylase and chromogranin 
in the same ratio as they are found in isolated chromaffin 
granules. Thus it was suggested that noradrenaline was 
released from the adrenal medulla by exocytosis, that is, the 
contents of the noradrenergic vesicles were extruded directly 
to the cell exterior and were not released through a hole in 
the cell membrane. This process demonstrated an absolute 
requirement for calcium and was termed stimulus-secretion 
coupling (Douglas, 1968).
Release of noradrenaline from nerve terminals of adrenergic- 
ally innervated peripheral organs can be demonstrated as the 
innervated end-organs can be isolated and the perfusate collected 
during stimulation analysed for the presence and quantity of 
neurotransmitter. When nerves to the spleen were stimulated, 
the ratio of noradrenaline to dopamine-3-hydroxylase released 
was greater than that found in vesicles isolated from the 
splenic nerve (Gewirtz and Kopin, 1970). This led to doubts 
about exocytosis as the mechanism of release of noradrenaline 
from sympathetic nerves.
Two mechanisms have been suggested to explain efflux of 
noradrenaline from sympathetic nerve terminals (Smith, 1973).
The first, exocytosis, involves fusion of neurotransmitter 
containing storage vesicles with the plasma membrane resulting 
in extrusion of vesicle contents through an opening made in 
the membrane. This process exhibits an absolute requirement 
for calcium and is thought to be analogous to stimulus- 
secretion coupling in the adrenal medulla. The second type,
which Is not calcium-dependent, and therefore distinct from 
calcium-dependent release of noradrenaline by nerve impulses, 
involved displacement of neurotransmitter from storage vesicles 
into the cytoplasm of the nerve terminals and passage of 
transmitter across the cell membrane into the extracellular 
space. A carrier located in the cell membrane would facilitate 
removal of neurotransmitter from the cell cytoplasm and 
protect it from deamination. The sympathomimetic amines, 
tyramine and amphetamine are thought to release noradrenaline 
from sympathetic nerve terminals in this way.
It is harder to demonstrate release of neurotransmitter 
from a given type of nerve ending in the central nervous 
system than in the peripheral nervous system (Cotman et al., 1976) 
as it is difficult to collect material released jni vivo. 
Synaptosomes offer many advantages for studying the release of 
neurotransmitters in the brain ÇBlaustein et al., 1972;
De Belleroche and Bradford, 1972a, b). For example, drugs can 
be applied without intervening diffusion barriers and neuro­
transmitter released can be collected quickly and directly. 
Depolarisation-induced release of noradrenaline (Blaustein et al., 
1972) and of dopamine (Patrick and Barchs, 1976) from synaptosomes 
was found to be calcium dependent and thus met the requirement 
of stimulus-secretion coupling. For this reason calcium- 
dependent release has been taken as evidence for exocytosis 
(mechanism 1) in the central as well, as the peripheral nervous 
system.
In this thesis, amphetamine (10 ^) stimulated release
of dopamine from striatal Pg fractions in the presence of 
2 mM EDTA at both. pH 6.6 and pH 7.2. This suggested that 
release of dopamine by amphetamine can occur, in part, by 
a non-exocytotic process. Amphetamine may thus release 
catecholamines in the central, as well as the peripheral, 
nervous system by displacement-diffusion (.mechanism 2).
Rutledge (1978) has described a model, analogous 
to the model proposed by Smith (1973) for release of noradrenaline 
from sympatheticneurons, to explain amphetamine-induced release 
of noradrenaline from isolated brain tissue (Fig. 25).
Amphetamine and sodium are cotransported into the nerve ending 
and as a result the carrier is on the inside of the membrane. 
Amphetamine then displaces noradrenaline from storage sites and 
noradrenaline can now bind to the carrier and be transported out 
of the nerve ending. Stimulation of dopamine release could 
also occur in this way (Rutledge, 1978).
Uretsky and Snodgrass (1977) reported that though
amphetamine (10 ^M) increased release of [^h ] catechols (dopa
and dopamine) formed from [^ h ] tyrosine by rat striatal slices 
in calcium-free medium the release produced by amphetamine was 
increased in medium containing 1.25, 2.5 and 10 mM calcium 
chloride. Further, De Belleroche et al. (1976) reported that 
amphetamine (1.19 x 10"^M)-induced release of dopamine
Cj dopa by striatal synaptosomes was significantly 
reduced in calcium-free medium containing 0.5 mîÆ EGTA.
These reports suggested that stimulation of release by 
amphetamine could occur in two ways, one of which was dependent 
on calcium (presumably exocytosis) and one independent of
Nerve EndingCell MembraneMedium
monoamine 
.oxidase y [storage,C-NA-NaC-NA+Na
NA + Na
Na
ATPase
sodium pump
Fig. 25. Diagram of a Postulated Mechanism by which
Noradrenaline is Released from Nerve Endings 
Uptake of NA occurs when the external sodium and NA 
concentrations are high relative to the respective free intra­
neuronal concentrations or when the carrier is facing the outside 
of the nerve ending. Efflux of NA is more likely when 
amphetamine is transported into the nerve ending. The carrier 
would now be on the inside of tbe membrane. Amphetamine would 
displace NA from binding sites thus making it available for 
binding to tbe carrier.
calcium (presumably displacement-diffusion). In the absence 
of calcium amphetamine could only stimulate release by 
displacement-diffusion while in the presence of calcium 
amphetamine could stimulate release by both displacement- 
diffusion and exocytosis. Thus the decrease in amphetamine- 
induced release of dopamine in the absence of calcium could be 
explained.
However, Arnold et al. (1977) reported that amphetamine
— 7 _ o
(10 -10” M)-induced release of endogenous dopamine from
slices of cerebral cortex did not depend on calcium. In 
contrast, potassium-induced release of endogenous dopamine was 
markedly calcium dependent. Thus amphetamine-induced release 
of endogenous as well as exogenous, dopamine occurs, at least 
in part, by a mechanism other than exocytosis. These authors 
also found that different proportions of endogenous and [ ]
(ie exogenous) dopamine were released by different concentrations 
of amphetamine. For example, amphetamine (10”^-10”^M)- 
released similar amounts of endogenous and exogenous dopamine 
but amphetamine (10”^-10”^M) released a greater percentage of 
endogenous than exogenous dopamine. This suggested that 
endogenous and exogenous dopamine were released from different 
pools. In conclusion, though it is difficult to compare the 
reported effects of calcium on amphetamine-induced release of 
dopamine as release may occur from different pools, the results 
obtained by the various authors, despite the different tissue 
preparation used, can still be explained in terms of the two 
release mechanisms, exocytosis and displacement-diffusion.
a. -LO
Tyramine stimulated release of dopamine from
striatal Pg fractions in the presence of either 1 mM EDTA 
or 1 mM calcium chloride (Patrick and Barchas, 1976), Tyramine 
may thus, like amphetamine, release dopamine from central nervous 
tissue by displacement-diffusion. This supports the idea that 
tyramine and amphetamine have identical effects on central and 
peripheral nerve endings (Raiteri and Levi, 1978).
Stimulation of release of dopamine from striatal Pg 
fractions by MIH and TRH occurred only in the presence of 
calcium chloride but stimulation of release of dopamine by 
amphetamine could occur also in the presence of EDTA. This 
suggested that release of dopamine by the hypothalamic hormones, 
MIH and TRH, and by amphetamine occurred in different ways.
As stimulation of release of dopamine required calcium, 
this suggested that MIH and TRH might release dopamine from 
storage vesicles by exocytosis (mechanism 1). This agrees 
with the work of Horst and Spirt (1974) who showed that TRH 
could not stimulate release of dopamine from striatal Pg 
fractions, if the storage vesicles were depleted by reserpine. 
These authors, however, examined the effect of TRH on dopamine 
release after 1 h. In this thesis, when release was studied 
under the conditions of Horst and Spirt (1974), release was linear 
for 2 rain. Thus the effect of drugs on a 2 min release of 
dopamine was studied. Similarly, Eitan and Hershkowitz (1977) 
only required a 3 min release of dopamine from striatal Pg 
fractions to show a stimulatory effect of potassium chloride 
which is thought to release dopamine from storage vesicles.
Results presented in this thesis showing a stimulation 
of release of dopamine by MIK do not agree with the preliminary 
reports of Kostrzewa et al. (1976) indicating that MIH did 
not alter the release of dopamine from dopamine-loaded Pg 
fractions. However, no details were given so it is not possible 
to compare their results with those in this thesis.
Greenberg et al. (1976) reported that when synaptosomes 
(S^ fraction) were incubated with [^H] MIH ( [2,3-^h ] pro-leu-gly 
NHg) uptake of peptide by synaptosomes was passive. However, 
as they did not identify the radiolabelled compound taken up, 
their conclusion may not be valid. But Parker et al. (1977)
O
found that when synaptosomes (S^ fraction) were incubated [ H] TRH 
pglu-his-[2,3-^H] pro NHg) the radiolabelled compound taken up 
was [^H] proline rather than [^H] TRH. In contrast, when 
metabolism of TRH was minimised by using a purified
synaptosomal preparation, uptake of radioactivity by synaptosomes 
was abolished. These authors therefore concluded that TRH, 
unlike amphetamine, did not penetrate synaptosomes.
TRH and MIH may therefore act on the synaptosomal membrane 
to stimulate release of dopamine by a calcium-dependent mechanism 
analogous to the mechanism of action of peptide hormones such 
as glucagon and insulin (for reviews see Bitensky and Gorman,
1972; Czech, 1977). The action of these peptide hormones is 
thought to be mediated by increased cellular concentrations 
of calcium. In addition, glucagon can stimulate adenylate 
cyclase to produce cAMP which promotes the phosphorylation of 
membrane proteins, thus increasing the permeability of the 
membrane to calcium.
Both cAMP and calcium mediate the release of pituitary 
hormones by their hypothalamic regulating hormones (Guillemin 
et al., 1971; Schally et al., 1972). However, the work 
of Cohn et al. (1976) and Green et al., (1976) suggested that 
the central effects of TRH were not mediated by cAMP. Further, 
MIH did not alter the levels of cAMP in various regions of the 
rat brain (Christiensen et al., 1976). Thus cAMP is unlikely 
to play a role in the behavioural effects of MIH and TRH.
4.2.3. Compartmentation of Dopamine in the Striatum
The results of release experiments in this thesis suggested 
that dopamine exists in two pools in striatal synaptosomes. 
Features of dopamine storage will now be described to provide 
a model of release and biosynthesis in striatal synaptosomes.
De Belleroche et al. (1976) identified two compartments 
of striatal dopamine by differential labelling with isotopic 
precursors, tyrosine and dopa, and from specific radioactivity 
measurements. Tyrosine provided a source for the dopamine 
pool synthesised and released in response to potassium 
depolarisation whereas dopa did not enter this pool. -The pool 
of dopamine formed from dopa was largely recovered from the 
incubation medium in the presence of amphetamine, though this 
pool was not released by depolarisation. This pool appeared 
to be prone to oxidation to DOPAC and HVA which are preferent­
ially released from synaptosomes.
Kuczenski (1975b) obtained evidence for two dopamine pools 
in synaptosomes using a different approach. His reasoning 
was as follows;-
The EDgQ for amphetamine-induced release of dopamine
-5from striatal synaptosomes was near 5 x 10 M (Azzaro and 
Rutledge, 1973), while the for accelerated dopamine
synthesis was almost 50-fold lower, near 1 x lO^^M. Similarly, 
the EDgQ for exchange of unlabelled dopamine in the medium with 
dopamine in the synaptosomes was near 5 x 10“^M, whereas 
the ED^q for inhibition of synaptosomal tyrosine hydroxylation 
by exogenous dopamine was near 5 x 10 M (Karobath, 1971). Thus 
it would appear that the inhibitory pool of dopamine is very 
small and does not achieve rapid equilibrium with the majority 
of exchangeable or amphetamine-releasable dopamine vitro.
There is other evidence to suggest that dopamine may 
exist in two pools in the striatum. After intraperitoneal 
injection of ct-methyl-p-tyrosine to rats, the dopamine 
concentration in the striatum declined biphasically (Doteuchi 
et al., 1974; Javoy and Glowinski, 1971). From this biphasic 
decline, Javoy and Glowinski (1971) inferred that there were 
two distinct storage forms of dopamine in dopaminergic nerve 
terminals, namely a functional pool of transmitter which 
contained about 26% of the total striatal dopamine and a main 
storage pool (74% of the total dopamine). The functional pool 
of dopamine turned over more rapidly than did the main storage 
pool. However, Doteuchi et al. (1974) suggested that the 
evidence for this interpretation was insufficient as a-methyl-p- 
tyrosine did not cause an immediate and complete inhibition of 
tyrosine hydroxylase.
The concentration of dopamine in striatal terminals
—2 "has been calculated to be greater than 10 M (Anden et al.,
1966). As the inhibitory constant for inhibition of striatal 
tyrosine hydroxylase by dopamine was reported to be 35 yM 
(Kuczenski and Mandell, 1972), less than 1% of total striatal 
dopamine would be sufficient to regulate tyrosine hydroxylase 
(Costa and Meek, 1974).
Newly synthesised striatal dopamine is thought to be 
released in preference to stored dopamine during nerve 
stimulation (Besson et al., 1969, 1971). In addition, the results 
of Weiner and his co-workers (Alousi and Weiner, 1966; Weiner 
and Rabadjya, 1968) with sympathetic nerves suggest that 
release of catecholamine with stimulation occurs with a 
concomitant decrease in the size of a small, chemically 
undetectable pool, which is functional in the regulation of 
tyrosine hydroxylase. Further, the behavioural effects of 
amphetamine are reserpine-resistant (Smith, 1963) and can be 
blocked by a-methyl-p-tyrosine (Weissman and Koe, 1965; Weissman 
et al., 1966). This also supports the suggestion of multiple 
pools of dopamine,
4...2',4 Regulation of Tyrosine Hydroxylase
There are a number of different mechanisms involved in the 
regulation of tyrosine hydroxylase, the rate-limiting step in 
the biosynthesis of catecholamines (Nagatsu et al., 1964).
One of the most important factors which regulate tyrosine 
hydroxylase is feedback inhibition by catechols, particularly 
dopamine (Kuczenski and Mandell, 1972), which competes with the
enzyme for the pteridine cofactor (Nagatsu et al., 1971).
Thus an Increase in dopamine synthesis could be achieved by 
increasing release of dopamine from a pool inhibiting tyrosine 
hydroxylase (Kuczenski, 1975b) or by altering the physical state 
of the enzyme (Kuczenski, 1975a), thus making it less sensitive 
to feedback inhibition by dopamine (Roth et al., 1975).
According to Kuczenski (1975a), tyrosine hydroxylase in 
striatal nerve endings exists in two states, namely, a soluble, 
less active form and a membrane-bound, activated form. The 
soluble form can be converted to the active form by the addition 
of calcium. Activation of tyrosine hydroxylase is associated 
with a ten-fold increase in affinity for the synthetic cofactor 
6,7-dimethyl-5,6,7,8-tetrahydropterin and a seven-fold increase 
in affinity for the substrate tyrosine. The inhibitory constants 
for inhibition by dopamine of the two forms of tyrosine hydro­
xylase were not given.
Tyrosine hydroxylase can be activated by enhanced neuronal 
activity. According to the model of Roth et al. (1975), an 
increase in impulse flow in dopaminergic neurons results in an 
increase in the frequency of depolarisation of the neuronal 
terminals with a consequent increase in the influx of calcium. 
Calcium then initiates a series of reactions which leads to 
activation of tyrosine hydroxylase via a cAMP-dependent protein 
kinase. Activation of tyrosine hydroxylase is mediated by 
a five-fold increase in affinity for the presumed natural 
cofactor tetrahydrobiopterin, a three-fold increase in affinity 
for the substrate tyrosine and six-fold decrease in affinity for 
dopamine.
However, dopaminergic unlike noradrenergic neurons 
paradoxically increase synthesis in response to a cessation 
of impulse flow (Roth et al., 1975), The most dramatic
change is the greater than 700-fold increase in the inhibitory 
constant for dopamine. The kinetic alterations, however, 
unlike those produced by increased impulse flow, are completely 
reversed by addition of calcium to the incubation medium.
Thus the increase in tyrosine hydroxylase activity which occurs 
in the striatum during cessation of impulse flow may occur as 
a result of a diminished influx of calcium ultimately resulting 
in an allosteric activation of tyrosine hydroxylase, thus 
making it less sensitive to feedback inhibition by dopamine 
(Roth et al, 1975). As indicated above, the role of calcium 
in the regulation of tyrosine hydroxylase is unclear.
Stimulation of dopamine receptors also reversed the 
increase in dopamine synthesis induced by blockade of impulse 
flow (Roth et al., 1975). This suggested that dopamine
receptors may play a direct role in the control of dopamine 
biosynthesis (Morgenroth et al., 1976b).
Results presented in this thesis showed that 0.85 mM 
calcium stimulated dopamine synthesis by striatal synaptosomes 
by 30%. This agrees with the work of Gutman and Segal (1973) 
who reported that calcium (0.05 - 0.2 mM) could stimulate 
tyrosine hydroxylase isolated from four different regions of the
rat brain including the striatum. However, Goldstein et al.
—  S
(1970) reported that addition of calcium (2 x 10 M) resulted 
in a 60% inhibition of dopamine synthesis in striatal slices.
In contrast, Morgenroth et al. (1976a) reported that addition
of the calcium chelator, EOT A (50 >iM) caused a marked increase 
in the activity of striatal tyrosine hydroxylase present in 
high speed supernatants. Calcium (100 jiM) had no effect 
on striatal tyrosine hydroxylase (Morgenroth et al., 1976a).
But Lerner et al. (1977) reported that neither EGTA (50 pM) 
nor calcium (100 yM) stimulated soluble striatal tyrosine 
hydroxylase. Further, Patrick et al. (1975) found that the 
addition of various concentrations (0.1 - 10 mM) of calcium 
to rat brain striatal synaptosomes did not significantly alter 
the basal synthesis rate and McGeer et al. (1967) reported that 
10"^M calcium had no significant effect on tyrosine hydroxylase 
activity in rat brain homogenates.
Thus despite the different preparations used there is 
considerable disagreement as to the effect of calcium on tyrosine 
hydroxylase. The stimulation observed is not related to an 
increase in impulse flow (Roth, et al. , 1975) but may be due 
to conversion of tyrosine hydroxylase from a soluble to a 
membrane-bound form with concomitant activation of the enzyme 
(Kuczenski, 1975a).
4.2.5. Relationship Between Release and Synthesis of Dopamine
Kuczenski (1975b) showed that amphetamine and tyramine 
could stimulate dopamine synthesis by striatal Pg fractions 
incubated in the presence of 2 mM EDTA. Further, neither 
drug altered the activity of tyrosine hydroxylase or dopa 
decarboxylase in the absence of synaptosomal integrity. He 
therefore concluded that stimulation of synthesis was a 
consequence of depletion of an inhibitory pool of dopamine in
contact with tyrosine hydroxylase. However, high concentrations
__ q
of amphetamine (10 M) inhibited tyrosine hydroxylase, 
presumably by movement of dopamine into the inhibitory pool.
In agreement with Kuczenski (1975b), it has been shown 
in this thesis that both tyramine and amphetamine stimulated 
dopamine synthesis by striatal Pg fractions incubated in the 
presence of 2 mM EDTA, maximum stimulation with tyramine and 
amphetamine occurring between lO^^M and IG^^M. Amphetamine 
(10 ^M) inhibited dopamine synthesis by 14% in agreement with 
the value of 18% obtained by Kuczenski (1975b). Tyramine 
(10 ^M) inhibited dopamine synthesis by 40% but Kuczenski 
(1975b) found that tyramine (10""^M) stimulated dopamine synthesis 
by 5%. These results support the idea that tyramine and 
amphetamine stimulate dopamine synthesis in the same way 
(Kuczenski, 1975b).
Consistent with the idea of an inhibitory pool was the 
observation that the stimulation of dopamine synthesis 
obtained with tyramine and amphetamine was inversely related 
to the basal rate of dopamine synthesis. Thus tyramine and 
amphetamine would only stimulate dopamine synthesis if there 
was a significant level of dopamine in the inhibitory pool.
This hypothesis could be tested by measuring the endogenous 
level of dopamine and tyrosine hydroxylase activity in the same 
synaptosomal preparation.
In contrast, tyramine (3.3 x 10 "^ M) inhibited dopamine 
synthesis by 44% in the presence of 1.7 mM calcium chloride.
This agrees with the work of Patrick and Barchas (1976) who
showed that 10”^M tyramine inhibited dopamine synthesis by 
48% in the presence of 1 mM calcium chloride. However, 
tyramine also inhibited dopamine synthesis (by 50%)
in the presence of 1 mM EGTA (Patrick and Barchas, 1976).
But Kuczenski (1975b) observed that stimulation not inhibition 
of dopamine synthesis occurred in the presence of EDTA. This 
discrepancy cannot be explained at present. The results of 
Patrick and Barchas (1976) are consistent with release of 
dopamine from storage vesicles into the cytoplasmic pool and 
transport of dopamine through the synaptosomal membrane.
Movement of dopamine into the inhibitory pool must occur in 
order that inhibition of dopamine synthesis be observed.
An alternative explanation is that dopamine might 
stimulate presynaptic dopamine receptors (autoreceptors) and 
thus inhibit dopamine synthesis (Starke et al., 1977) in the 
presence of EGTA but not in the presence of EDTA. However, stim­
ulation of autoreceptors also inhibited dopamine release 
(Starke et al., 1977). This is in conflict with the results 
of Patrick and Barchas (1976) who observed stimulation of 
release in the presence of EGTA.
Depolarising agents, for example veratridine, stimulated 
release of dopamine from striatal P^ fractions (Patrick et al., 
1975; Patrick and Barchas, 1976) by a calcium-dependent 
mechanism. Stimulation of dopamine synthesis also occurred, 
as a result of diminished end-product inhibition of tyrosine 
hydroxylase. Thus release must occur from both, inhibitory 
and vesicular pools.
Reserpine, which, depletes amine storage vesicles, was 
found to inhibit dopamine synthesis in the presence of 
EDTA (2 mM) (Kuczenski, 1975b), and also in the presence 
of calcium chloride (1 mM) (Patrick, and Barchas, 1974), 
an effect consistent with movement of vesicular dopamine into 
an inhibitory pool in contact with tyrosine hydroxylase.
Thus releasing agents will have different effects on 
synthesis, depending on whether they release dopamine from 
a vesicular or an inhibitory pool.
The hypothalamic hormones MIH and TRH stimulated release 
of dopamine from striatal P^ fractions but stimulation of 
release by MIH and TRH differed from that of amphetamine, 
the former being calcium-dependent, the latter independent 
of calcium. This suggested that MIH and TRH did not release 
dopamine from an inhibitory pool as did amphetamine and 
tyramine, but released dopamine from a different, possibly 
vesicular, pool. This difference in release was reflected 
in the synthesis studies. Amphetamine and tyramine 
stimulated dopamine synthesis in the presence of 2 mM EDTA, 
but no obvious stimulatory effect of TRH on dopamine synthesis 
was observed, though at high basal rates of dopamine synthesis 
TRH had an inhibitory effect. In agreement with Patrick and 
Barchas (1976) tyramine inhibited dopamine synthesis in the 
presence of 1.7 mM calcium chloride, but MIH and TRH did not 
alter the rate of dopamine synthesis under these conditions.
There is a parallel between the actions of TRH and 
methylphenidate, a-phenyl-2-piperidine acetic acid methyl ester
Like TRH, methylphenidate can induce stereotyped behaviour 
and release dopamine from striatal Pg fractions (Kuczenski 
and Segal, 1975). However, methylphenidate was less 
efficient than amphetamine in stimulating dopamine synthesis.
The behavioural effects of methylphenidate, in contrast to 
those of amphetamine, were sensitive to reserpine but 
insensitive to a-methyl-p-tyrosine. This suggests that 
methylphenidate, like TRH (Horst and Spirt, 1974) released 
dopamine from reserpine-sensitive vesicular stores and not, 
like amphetamine, from a pool inhibiting tyrosine hydroxylase 
(Kuczenski, 1975b).
4,2.6. Relationship Between the Biochemical and Behavioural 
Effects of MIH and TRH
Table 31 summarises the effects of the sympathomimetic 
amines, tyramine and amphetamine, and the hypothalamic hormones, 
MIH and TRH, on release and synthesis of dopamine. The main 
conclusion is that MIH and TRH can, like amphetamine, stimulate 
release of dopamine from striatal synaptosomes in the presence 
of calcium chloride. Unlike amphetamine, MIH and TRH did not 
stimulate either the release or synthesis of dopamine in the 
presence of EDTA. MIH inhibited dopamine release, while
TRH had no effect. Neither MIH nor TRH influenced dopamine 
synthesis. Tyramine inhibited synthesis of dopamine 
in the presence of calcium (Patrick et al, 1975); MIH and 
TRH had no effect. Another difference between the hypo­
thalamic hormones and amphetamine is that MIH and TRH did
{Table 31. Summary of Effects of Drugs bn Release and
Synthesis of Dopamine
Drug
Release Biosynthesis
EDTA Calciumchlordie EDTA
Calcium
chloride
Amphetamine 4- + + ND
Tyramine ND ND + -
MIH - 4" 0 0
TRH 0 + 0 0
ND not determined
O no effect
+ stimulation
inhibition
not inhibit reuptake of catecholamines (Horst and Spirt,
1974; Kostrzewa et al., 1976; Tuomisto and Mannisto, 1973) 
nor did they inhibit oxidative deamination of catecholamines 
(Breese et al., 1974; this work).
Amphetamine is thought to produce its behavioural effects
chiefly by interaction with central dopaminergic neurons
(Moore, 1977). The principal biochemical effects of
amphetamine are stimulation of release of amine from nerve
terminals (Azzaro and Rutledge, 1973; Besson et al., 1969)
and inhibtion of neuronal uptake (Azzaro et al., 1974;
Ross and Renyi, 1964). At higher concentrations of
— 4 —Pamphetamine (10 -10 M) inhibition of monomine oxidase can
occur (Glowinski et al., 1966; Rutledge, 1970). Stimulation 
of dopamine synthesis, through release of tyrosine hydro­
xylase from feedback inhibition by dopamine, has also been 
reported (Kuczenski, 1975b).
As indicated above, there are differences at the 
biochemical level between the effects of the hypothalamic 
hormones, MIH and TRH, and amphetamine but one can still 
account for the behavioural effects of the hypothalamic hormones 
in which dopaminergic neurons may be the site of action.
Both amphetamine and the hypothalamic hormones, MIH and TRH, 
stimulate release of dopamine, but they do it in different 
ways. Both result in an increase in concentration of 
dopamine in the synaptic cleft which would activate the 
post-synaptic receptor and presumably lead to the behavioural 
changes. Thus increased release of dopamine newly synthesised
from L-dopa could explain the potentiation of L-dopa by MIH 
and TRH (Plotnikoff and Kastin, 1976) and also the possible 
beneficial effects of MIH in Parkinson's disease (Barbeau, 
1974; Kastin et al., 1976). Further TRH could,like amphet­
amine, potentiate any imbalance in dopamine content between 
left and right sides of the brain and thus induce rotational 
behaviour (Cohn et al., 1975).
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